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A complex network of inflammatory cascades is triggered in response to onset of cerebral 
ischemia. Key inflammatory markers have been demonstrated to directly exert detrimental effects 
to the brain after cerebral ischemia. Furthermore, strong correlations have been found between the 
status of peripheral inflammation and outcomes after ischemic stroke. Many previous studies on 
the association between inflammatory markers and stroke outcomes were conducted at the acute 
stage after stroke. However, stroke severity has been shown to be strongly correlated with 
inflammatory markers at the acute stage, and stroke severity itself is a strong predictor for 
outcome. Hence the association between inflammatory marker and stroke outcome need to be 
ascertained in a cohort of stroke survivors with homogeneous stroke severities. Inﬂammation is 
an important mechanism underlying dementia and cognitive decline, including vascular cognitive 
impairment. Therefore, inflammatory markers may also be a prognostic marker for cognitive 
outcomes after stroke. Accordingly, the present thesis evaluated the prognostic values of 
inflammatory markers in a prospective cohort of non-disabled stroke patients who were at the 
convalescent stage, free of potential confounding effects by stroke severity. The 24 markers 
investigated in this thesis were selected from key factors in mechanisms known to contribute to 
post-ischemic inflammatory processes, namely, peripheral leukocyte recruitment, pro-
inflammation, anti-inflammation, recovery and remodeling. 311 patients who were within six 
months of a transient ischemic attack or minor ischemic stroke (grade three or less on the 
modified Rankin Scale) were followed for up to five years. Baseline serum samples were 
collected at a median of 47 days after the qualifying event. Cox regression analyses were 
performed to determine whether inflammatory marker levels were associated with risk of death, 
recurrent vascular events, dependency, and incident dementia. Logistic regression analyses were 
performed to determine whether inflammatory marker levels were associated with risk of 
significant cognitive decline. A higher serum level of soluble vascular cellular adhesion 





(HR) per standard deviation (SD) increase of square-root transformed levels, 1.85; 95% 
confidence interval (CI), 1.07-3.19), and recurrent stroke (HR per SD increase of square-root 
transformed levels, 1.62; 95% CI, 1.08-2.41). A higher serum level of platelet-derived growth 
factor-AB/BB was independently associated with a lower risk of recurrent vascular events (HR 
per SD increase of square-root transformed levels, 0.60; 95% CI, 0.42-0.85). With regard to 
cognitive outcomes, a higher serum level of vascular endothelial growth factor was independently 
associated with a lower risk of significant cognitive decline (odds ratio per SD increase of square-
root transformed levels, 0.45; 95% CI, 0.26-0.77). The other markers were not associated with 
any outcome of interest. In conclusion, sVCAM-1, PDGF-AB/BB, and VEGF were predictive for 
outcomes in a cohort of non-disabled stroke survivors. Therefore, they may potentially serve as 
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Stroke is one of the leading causes of mortality and morbidity worldwide
1
. Post-stroke deficits 
include partial paralysis, difficulty with movement, inability to see one side of the visual field, 
and vascular cognitive impairment (VCI). Despite the devastating consequences of stroke, the 
only FDA-approved treatment is thrombolysis with recombinant tissue plasminogen activator (rt-
PA)
2
, with a narrow therapeutic window of 4.5 hours within onset of symptoms and serious 
potential complications such as hemorrhagic transformation and edema
3, 4
.    
Stroke is caused by an immediate loss of oxygen and glucose to the cerebral tissue due to 
disturbed blood supply to the brain. Stroke can be broadly classified into two categories: ischemic 
stroke and hemorrhagic stroke. Ischemic stroke is caused by interruption of blood supply to part 
of the brain, due to thrombosis (a blood clot formed locally), embolism (an embolus from other 
parts of body), systemic hypoperfusion, or venous thrombosis (locally increased venous pressure). 
On the other hand, hemorrhagic stroke is caused by a rupture of a blood vessel or an abnormal 
vessel structure.   
In the ischemic brain, two types of tissue are distinguished: the infarct core and its surrounding 
zone, the penumbra
5
. The two types of tissue are characterized by two different types of cell death, 
necrosis and apoptosis, respectively. Necrosis is the premature death of cells, whereas apoptosis, 
or programmed cell death, is characterized by the activation of a cascade which eventually leads 
to characteristic cell morphological changes and cell death. Apoptosis mostly occurs in the 
penumbra, as opposed to the necrotic cell death taking place in the infarct core. In the infarct core, 
a massive disruption of blood supply leads to breakdown of oxygen and glucose metabolism, 
depletion of energy, and loss of cellular integrity, resulting in necrotic cell death within minutes. 





infarct core, cerebral tissue in the penumbra is still viable, and can be salvaged with timely 
restoration of blood supply or appropriate neuroprotective intervention. The survival or eventual 
apoptosis of these cells in the penumbra are determined by inflammatory processes.  
Upon onset of ischemia, an ischemic cascade is triggered. Since the brain is a highly energy 
demanding organ, the decrease in cerebral blood flow leads to disruption of the supply of oxygen 
and glucose thereby resulting in reduced production of ATP. The reduced ATP leads to 
malfunctioning of ion pumps that regulate the net charge difference across the cell membrane. 
Consequently, the membrane potential increases and an action potential is released which in turn 
triggers release of excitotoxic neurotransmitters, including glutamate, glycine, and GABA, into 
the extracellular compartment. Subsequently, the accumulated glutamate activates glutamate-
mediated channels such as NMDA-, AMPA- and metabotropic glutamate receptors), which 






. The effect 
of the series of processes is a disturbed ion homeostasis. The osmotic pressure leads to passive 
influx of water into the cells, hence necrotic cell death in the infarct core.  
In the penumbra where necrotic cell death generally does not take place, excitotoxicity may 
trigger several cytotoxic molecular pathways. One of such pathways is oxidative stress. 
Intracellular Ca
2+
 activates calcium-calmodulin-dependent nitric oxide synthase, which promotes 
synthesis of the highly reactive peroxy-nitrite radical from superoxide and nitric oxide
6
. Free 
oxygen radicals can react with and damage any cellular component including amino acids, DNA, 
and lipids, thereby mediating apoptosis.  
Another pathway initiated by excitotoxicity is the inflammatory cascade. To start with, 
inflammatory cytokines, including tumor necrosis factor (TNF)-α and interleukin (IL)-1β are 
produced locally, which in turn promote the production of other cytokines including IL-6 and IL-





also triggered, which facilitates infiltration of circulating leukocytes into the ischemic brain. The 
leukocytes recruited from the periphery react with the endothelial cells of the capillary, and may 
cause occlusion of the artery
7
; meanwhile the leukocytes also promote release of vasoactive 
agents, which reduce vascular reactivity
8
. Both processes prevent complete recovery of cerebral 
blood flow in the ischemic area. In addition, the recruited leukocytes stimulate the release of 
proteases such as matrix-metalloproteases (MMPs), which cleaves the basal lamina and disrupt 
the integrity of the endothelial wall of the blood-brain barrier (BBB). The more permeable BBB 
facilitates influx of peripheral leukocytes, water, as well as erythrocytes, which may result in 
cerebral edema or hemorrhagic transformation
9, 10
.  
1.2 Post-ischemic inflammation 
Although the brain was once considered as an immune-privileged organ due to the existence of 
the BBB which restricts the exchange of solutes between circulating blood and the brain 
extracellular fluid of the central nervous system; over the last decade, emerging experimental and 
clinical evidences have suggested a cross-talk between the immune and nervous systems, and 
inflammation is increasing recognized not only as an essential element contributing to all stages 
of the ischemic cascade, but also a key contributor to the pathophysiology of stroke
11
.  
Post-ischemic signaling process takes place immediately in response to onset of ischemia. 
Hypoxia, shear stress, and oxidative stress trigger the coagulation cascade, which results in 
complement, platelet, and activation of the cerebral endothelium
12-15
. The fibrin formed in turn 
sequesters platelets and leukocytes, causing microvascular occlusions
16, 17
. Adhesion molecule P-
selectin is rapidly exported to the surface of platelets and the endothelium
18
. Activated brain 
endothelial cells express a wide variety of mediators including cytokines (IL-1α, IL-1β, TNF), 
chemokines (RANTES, CXCL4), proteases (MMP-9, MMP-8), free radicals (NO, superoxide), 
vasoactive substances (prostanoids, leukotrienes), and adhesion molecules (L-selectin, ICAM-
1)
19-22





and protease activities increase the permeability of the BBB, which under normal conditions 
functions as a barrier between the brain parenchyma and circulation, thereby limiting the 
exchange of cells and bioactive mediators. Following the opening of the BBB, blood-borne 
leukocytes (neutrophils, monocytes, dendritic cells) and bioactive mediators can infiltrate into the 
brain parenchyma, and vice versa
23, 24
. These infiltrated leukocytes, as demonstrated by 
experimental models of cerebral ischemia, play a pivotal role in furthering the damage to the 
ischemic brain. For example, neutrophils may exacerbate the compromised integrity of the BBB 
directly by secreting MMP-9 or indirectly by stimulating MMP-9 secretion from the 
endothelium
25, 26
. Also, RANTES-deficient mice have been shown to exhibit reduced plasma 
levels of cytokines (IL-6, IL-10, and IL-12), infarct size and BBB damage, compared with wild-
type mice after middle cerebral artery occlusion (MCAO)
27
. Microglias, the resident macrophages 
in the brain, are considered to be the main cellular source of cytokines and chemokines
28-30
. 
Correlations of microglia activation and brain levels of cytokines with ischemic injury have been 
established
31
. However, recent findings also suggest a role for the astrocytes in secreting 
inflammatory mediators such as NO, IL-1, and MMPs
32-34
.   
The effects of immunological responses to cerebral ischemia are not restricted locally to the brain, 
but are also present in the periphery. It has been established that a prompt and long-lasting 
peripheral inflammation is elicited after onset of cerebral ischemia
31
. Moreover, extensive clinical 
studies have reported altered levels of leucocyte count, soluble adhesion molecules, acute-phase 
proteins, cytokines, and proteases in the circulation
31
, and these molecules may be implicated in 
the formation of ischemic injury
31
. Besides, strong correlations between levels of circulating 
levels of inflammatory mediators and stroke outcomes have been shown
31
, thus an exhaustive 












1.2.1 Cellular adhesion molecules (CAMs) 
Peripheral leukocytes migrate to the infarct site within 12 hours after the onset of cerebral 
ischemia
35
, and the recruited leukocytes have been shown to contribute to the growth of the 
infarct core into the surrounding penumbra
36-38
. Cellular adhesion molecules facilitate the 
adhesion of leukocytes to the cerebral endothelial and their subsequent migration from the vessels 
into the brain parenchyma. There are three main families of CAMs with different structures: 
integrins, immunoglobulin family, and selectins
39
. Under physiological conditions, expression of 
CAMs is maintained at very low levels
40
; however, under inflammatory conditions, expression of 
CAMs is induced on both the surfaces of endothelium and leukocytes by cytokines
41
. Soluble 
forms of the CAMs (sCAMs) are produced when the membrane-bound forms are cleaved and 
shed into the circulation.  
One of the most extensively studied CAM in stroke is ICAM-1, which belong to the 
immunoglobulin family. In contrast to the selectins, which mediate the initial low-affinity 
interaction between leukocytes and endothelium, the immunoglobulin family of CAMs mediates 
the tight attachment of leukocytes to the endothelium and subsequent transmembrane migration. 
Pro-inflammatory cytokines, especially IL-1 and TNF-α, are potent inducers of ICAM-1 
expression on the endothelial surface
42
. Both rodent and nonhuman primate studies have 
demonstrated elevations of ICAM-1 mRNA and protein after focal cerebral ischemia
43
. As to the 
effect of ICAM-1 in worsening ischemic injury, an autopsy study showed more ICAM-1 
expression and PMN accumulation in microvessels of ischemic infarct, compared with the 
contralateral hemisphere
44
. This finding suggests the role of ICAM-1 in facilitating the infiltration 
of peripheral-derived PMN leukocytes into the ischemic parenchyma
39
. ICAM-1-deficient mice 
exhibited a reduction in infarct size after MCAO, compared with wild-type mice
45
. Furthermore, 
inhibition of ICAM-1 by monoclonal antibody decreased infarct size, tissue damage, neutrophil 
infiltration, and apoptosis after cerebral ischemia
45-48





sICAM-1 in stroke patients, and these elevated levels correlated with stroke severity
49
 as well as 
the risk of stroke outcomes including death, recurrent vascular events, and early neurological 
deterioration
50-52
.   
A less well studied member of the immunoglobulin family, VCAM-1, has also been shown to be 
strongly induced by IL-1
53
. Levels of sVCAM-1 in stroke patients were similar to that of controls 
upon stroke onset, and no significant diagnostic value was found for sVCAM-1 levels measured 
within 72 hours of symptom onset in ischemic stroke patients
54, 55
. However, sVCAM-1 levels 
increased over time, and its levels have been demonstrated to become significantly different 
between stroke patients and controls 90 days after the index event
54
. In patients recruited within 
1-3 months after stroke onset who did not receive anti-coagulation treatment, those with sVCAM-





Chemokines are a family of low-molecular-weight polypeptides secreted by cells. Chemokines 
share a common structure of 4 cysteine residues and bind to specific G protein-coupled 
receptors
57
. Production of chemokines can be stimulated under inflammatory conditions by pro-
inflammatory cytokines such as IL-1 and TNF-α58. The major function of chemokines is to guide 
the migration of leukocytes such as neutrophils and macrophages, which follow a signal of 
increasing chemokine concentrations to the source of the chemokine (usually the site of infection). 
In cerebral ischemia, chemokine-driven migration of peripheral leukocytes into the infarct area 
has been implicated in the exacerbation of ischemic injury
41, 59
. Recent work has demonstrated an 
elevation of chemokine levels after MCAO in mice and correlated chemokine expression to 
infarct volume
41, 59
. Furthermore, inhibition of chemokines has been shown to be neuroprotective 







Monocyte chemoattractant protein-1 (MCP-1), or CC chemokine ligand-1 (CCL2), is a potent 
attractant for mononuclear cells, such as T cells, dendritic cells, eosinophils, natural killer cells, 
mast cells and basophils
60
. MCP-1 has been previously implicated in cerebral ischemia in various 
animal studies. For example, in rats undergone transient or permanent MCAO, mRNA of MCP-1 
was detected in the resident astrocytes and microglia in the brain at 6 hours, and the mRNA level 
was persistently high up until 48 hours
61, 62
. At 4 days after MCAO, MCP-1 mRNA was detected 
in the macrophages of the cerebral infarct
63
. Moreover, IL-1β and TNF-α have been shown to 
induce MCP-1 mRNA expression in vitro, and upregulation of MCP-1 expression followed that 
of IL-1β and TNF-α in vivo, which serves as a supporting evidence for the hypothesis that 
chemokine expression is induced by cytokines
63, 64
. Apart from chemoattraction, MCP-1 has also 
been found to possess neuroprotective effects in human or rodent glial-neuronal co-cultures
65
. 
Mice deficient of MCP-1 receptors had reduced infarct size after ischemic-reperfusion injury, 
which is consistent with the hypothesis that inhibition of MCP-1 function had protective effects 
against ischemic-reperfusion injury by decreasing edema, leukocyte infiltration, and the 
expression of inflammatory mediators
66
. Clinically, increased MCP-1 levels were observed in the 
CSF, but not sera, of patients within 24 hours of onset of ischemia
67
. Another study reported 
elevated MCP-1 in the sera of patients with a history of ischemic stroke, compared with healthy 




Regulated on activation, normal T-cell expressed and secreted (RANTES), or CCL-5, is produced 
by a variety of cells, including T-lymphocytes, platelets, endothelial cells, smooth muscle cells, 
and glial cells
69
. Besides chemotactic properties, aggregates of RANTES on cell surfaces can 
serve as potent activators of leukocytes
27
. Furthermore, as with MCP-1, RANTES also have 
neuroprotective effects
65
. RANTES has also been demonstrated to contribute to the inflammatory, 





exhibited reduced leukocyte recruitment, BBB permeability, and infarct size after MCAO, 
compared with wild-type mice
27
. Moreover, despite similar levels in the brain, levels of IL-6, IL-
10, and IL-12 were lower in RANTES-deficient mice, compared with wild-types
27
. Clinically, 
higher RANTES levels were found to independently predict incidence of first-ever ischemic 
stroke in asymptomatic men in a 10-year follow-up study
70
. 
Monokine induced by gamma interferon (MIG), or Chemokine (C-X-C motif) ligand 9 (CXCL9), 
is a member of the CXC chemokine family. It can be induced in macrophages and other cells in 
response to interferon (IFN)-γ, and directs the migration of T-lymphocytes71. Apart from the 
finding that MIG levels in the brain were elevated during the late phase of cerebral would healing 
in mice
72
, the role of MIG in cerebral ischemia remains largely unclear.  
1.2.3 Pro-inflammatory cytokines  
Thus far, the roles of CAMs and chemokines in the process of peripheral leukocyte recruitment 
have been discussed. Nevertheless, the expression of these important mediators depends on 
upstream signaling pathways, in which pro-inflammatory cytokines play key roles. Cytokines are 
a class of low-molecular-weight glycoprotein molecules produced a vast body of cell types, 
including endothelial cells, platelets, leukocytes, and fibroblasts
39
. They are secreted in response 
to activating signals, and through specific binding to cytokine receptors and activating secondary 
messenger and subsequently downstream signaling pathways, regulate cellular behaviors and act 
as intercellular messengers. Pro-inflammatory cytokines may exert a wide range of effects to the 
brain, and whether these effects are beneficial or detrimental to the brain depends on dose, target, 
and timing of the actions
73, 74
. For example, pro-inflammatory cytokines can stimulate expression 
of CAMs, modulate levels of mediators of thrombogenesis (inhibiting tissue plasminogen 
activator and protein S, and increase tissue factor, plasminogen-activating inhibitor-1 and platelet-
activating factor), and activate glia, neurons, and the endothelium
75-78
. A large number of studies 





settings, and they are considered to be one of the principal mediators of the immunological 
responses after cerebral ischemia.    
IL-1, one of the most studied cytokines, exists in two different forms (IL-1α and IL-1β). Two 
main IL-1 receptors have been identified, namely, type I and type II receptors. Type I receptors 
are found on various cell types, and have similar affinity for both IL-1α and IL-1β, while type II 
receptors are found on neutrophils, B-lymphocytes, and macrophages, and preferably bind IL-
1β79. IL-1α levels are strongly elevated at the early and late stages of cerebral ischemia. 
Polymorphisms of the IL-1α gene have an effect on the level of cytokine production, and are 
significantly associated with the development of ischemic stroke
80
. It has been postulated that IL-
1 gene polymorphisms indirectly affect stroke development via the risk factors for atherosclerotic 
vascular disease, rather than directly causing the occurrence of ischemic stroke
81
.         
IL-2 is a potent immunostimulatory polypeptide which plays essential roles for the growth and 
function of T cells under inflammatory conditions, thus mediating the amplification of immune 
response to antigens. Relatively little is known about the role of IL-2 in ischemic stroke. Serum 
levels of IL-2 were found to be associated with intima-media thickness, which is a predictor of 
stroke and vascular disease
82
. In a clinical study in acute ischemic stroke patients admitted to the 
hospital within 24 hours of ischemic onset, IL-2 levels in the serum were found to be elevated at 
point of admission and 24 hours after admission
83
. Furthermore, IL-2 levels were decreased in 
patients who improved, but not in those whose symptoms deteriorated
83
. 
IL-12 is encoded by two separate genes, IL-12A (p35) and IL-12B (p40), from which a 
heterodimer or a homodimer of p40 can be formed. IL-12 is produced by dendritic cells and 
macrophages in response to antigenic stimulation, and it facilitates the growth, differentiation, 
and function of T-lymphocytes. Also, IL-12 stimulates the production of IFN-γ and TNF-α by T 





within 24 hours of ischemic onset, compared with matched controls
84
. Moreover, IL-12 levels 
significantly correlated with stroke severity as measured by the Scandinavian Stroke Scale (SSS) 
and the Barthel Index
84
, which suggests a role of IL-12 in the pathophysiology of ischemic stroke. 
On the other hand, IL-12 (p40) has been found to be elevated during the early phase of cerebral 
wound healing in mice
72
. 
IL-15 shares structural similarity to IL-2, and is secreted by mononuclear phagocytes following 
infections. Under hypoxic conditions, IL-15 can be expressed by endothelial cells. The main 
function of IL-15 is to induce the proliferation of natural killer cells. Though IL-15 may be 




IL-16 is secreted by a variety of cells including lymphocytes and epithelial cells. It is 
characterized as a chemoattractant for CD4-expressing leukocytes, and it has been shown to 
induce IL-1β, IL-6 and TNF-α expression in monocytes. IL-16 is expressed by microglial cells in 
the brain, and has been suggested to modify the post-ischemic microenvironment through acting 
as a chemoattractant for CD4-expressing lymphocytes across the BBB
86
. IL-16 has also been 
shown to modulate apoptosis. 
IL-17 is a newly characterized cytokine produced by T helper 17 cells under the stimulation by 
IL-23. IL-17 can induce IL-6, IL-8, granulocyte colony stimulating factor, and ICAM-1 
production by stroma cells such as fibroblasts, endothelial, and epithelial cells. Higher IL-17 
mRNA levels, peaking at day 6, have been detected in the ischemic hemisphere of rats undergone 
permanent MCAO compared with the contralateral hemisphere, which were probably produced 
by neurological cells in the ischemic region
87
. Similarly, levels of IL-17 mRNA were higher in 
the ischemic hemisphere of human patients compared with the contralateral hemisphere, which 
peaked at day 3-5
87





mononuclear cells and correlated with the SSS scores of stroke patients
88
. Moreover, inhibiting 




IFN-γ is produced by activated CD4, CD8 T cells, and Natural Kill (NK) cells90. Since IFN-γ is 
not produced by resident cells in the brain, its secretion in the brain depends on infiltrated 
peripheral-derived leukocytes after BBB breakdown
75
. Apart from activation of macrophages and 
induction of various cytokines, IFN-γ can promote the production class II major 
histocompatibility complex (MHC II), which may lead to brain necrosis, since macrophages 
differentiate antigens through recognizing MHC II
75
. Additionally, IFN-γ may induce NO 
synthase production, thereby exerting cytotoxic effects to brain cells
91
. IFN-γ-deficient mice 
displayed significantly reduced leukocyte and platelet adhesion compared with wild-type mice 
undergone MCAO and reperfusion
92
.    
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine secreted by T cells, 
macrophages, neurons, and endothelial cells, and plays a pivotal role in inﬂammatory diseases 
such as atherosclerosis. MIF has general pro-inflammatory effects via its antagonistic action 
against the immunosuppressive effects of glucocorticoids
93
. MIF has also been shown to induce 
secretion of TNF-α, IL-1β, IL-6, IL-8, and MMPs by macrophages in rheumatoid arthritis94-97, 
and it may facilitate leukocyte migration through upregulation of VCAM-1 and ICAM-1
98
. 
Besides, MIF is a potent angiogenic factor
99
. MIF was increased in cultured cortical neurons 
exposed to oxygen and glucose deprivation, and cell death was reduced by inhibiting MIF
100
. 
Similarly, MIF was elevated in the peri-infarct region of rats undergone transient MCAO, and 
disruption of MIF gene decreased infarct size and improved neurological function
100
. Clinical 
study has demonstrated that MIF was increased at both mRNA and protein levels in stroke 
patients, peaking at 24 hours after ischemic onset, and correlated with the severity of stroke
101





1.2.4 Acute-phase proteins 
C-reactive protein (CRP) is one of the acute-phase proteins (APPs) synthesized by the liver 
hepatocytes in response to IL-1, IL-6, and TNF under a wide range of chronic and acute 
inflammatory conditions
102, 103
, when CRP levels may increase dramatically (100-fold or more of 
normal levels). Physiological functions of CRP include activating classic complement system
104
, 
binding to immunoglobulin receptors on immune cell surfaces, apoptotic cells, and oxidized low-
density lipoproteins, stimulating the production of cytokines, and inducing expression of adhesion 
molecules (E-selectin,VCAM-1, and ICAM-1) by endothelial cells and MCP-1
105-109
. These facts 
suggest a possible role of CRP in exaggerating the ischemic cerebral injury. Besides, CRP may be 
implicated in the initiation and progression of atherosclerosis and is associated with plaque 
vulnerability and occurrence of acute thrombotic events
110, 111
. Moreover, due to its rapid 
synthesis and long half-life (19 hours)
112
, CRP also serves as a sensitive peripheral marker for 
inflammation. Circulating levels of CRP have been found to be elevated after acute ischemic 
stroke in a large body of clinical studies, and higher CRP levels have been reported to predict 
various outcomes including death, recurrent vascular events, and dependency
113-116
. Thus, CRP 
has attracted much attention as a potential biomarker for stroke; however, it is being argued that 
the supporting data is not yet conclusive
117
.      
1.2.5 Apoptotic stimuli 
Apoptosis occurs with a similar time frame as inflammation during stroke
118
, and can be triggered 
by the intrinsic and extrinsic pathways. Under the setting of cerebral ischemia, the intrinsic 
pathway is triggered by the elevated intracellular levels of Ca
2+
, ROS, and glutamate
119-122
, while 
the extrinsic pathway is triggered by activation of the FAS-receptor by ligands such as TNF, Fas 
ligand, and TNF-related apoptosis-inducing ligand (TRAIL). Activation of the apoptosis cascade 
eventually leads to the cleavage-activation of the caspases, proteases which are synthesized as 





compartments and molecules after activation. Caspases 1, 3, 8, and 9 have been found to be 
implicated in cerebral ischemia
118
. Caspase 1 contributes to the activation of cytokines, thus 
connecting inflammation with apoptosis
120, 121, 123
. In addition, inhibition of Caspase 3 has been 
shown to be neuroprotective in animal stroke models
124, 125
.     
TRAIL is a ligand that induces apoptosis via the extrinsic pathway by binding to death receptors 
DR4 and DR5
126
. In the brain, TRAIL is mainly released de novo by activated microglia, 
astrocytes, and peripheral-derived leukocytes, and it promotes apoptosis of neurons and glia 
during cerebral ischemia
127
. Levels of TRAIL mRNA are increased in response to cerebral 
ischemia
128
. Following immunosuppressive treatment with tacrolimus, TRAIL levels were 
decreased, neuroprotective effects were observed, and ischemic injury was ameliorated
128
. 
Furthermore, blocking the interaction between TRAIL and endogenous DR5 with soluble 




1.2.6 Anti-inflammatory cytokines 
Post-ischemic inflammation is a self-constraining process that eventually diminishes and prepares 
for the structural remodeling and functional recovery of the brain
130
. Although the exact elements 
regulating the resolution of post-ischemic inflammation are poorly understood, it is believed that 
it is an active process under the control of various mediators, as opposed to a passive process due 
to exhaustion of pro-inflammatory signals
131
. One major step involved in this process is 
upregulation of anti-inflammatory cytokines, which are a series of immunoregulatory molecules 
that counteract the effects of pro-inflammatory cytokines and reduce inflammatory responses. 
Nevertheless, almost all of the anti-inflammatory cytokines to some extent also possess some pro-
inflammatory properties
73
. The net effect of a cytokine therefore depends on various factors such 





IL-1 receptor antagonist (IL-1ra) is an endogeneous inhibitor of all known actions of IL-1α and 
IL-1β by competitive binding with equal or greater affinity to type I IL-1 receptor and occupying 
the binding sites. Allele 2 of a variable number tandem repeat of the IL-1ra gene, which is found 
in 25% of stroke patients, has been reported to contribute to genetic risk for ischemic stroke
132
. 
Intracerebroventricular or peripheral administration of IL-1ra 3 hours after transient MCAO or 8-
12 hours after global ischemia reduced lesion size, edema, glial activation, peripheral leukocyte 
infiltration, promoted neuronal survival, and improved behavioral outcomes
133-135
. A randomized 
phase II trial of IL-1ra in 34 patients recruited within 6 hours of ischemic onset showed that 
neutrophil and total leukocyte count, C-reactive protein (CRP), and IL-6 levels were reduced in 
IL-1ra treated patients compared with patients who received placebo
136
. In patients with cortical 
infarcts, those who received IL-1ra also exhibited better clinical outcome at 3 months
136
.      
IL-4 is a produced by T cells, mast cells, basophils, macrophages, and monocytes. IL-4 is a potent 
inhibitor of various pro-inflammatory cytokines, including IL-1, TNF-α, IL-6, and IL-8; on the 
other hand, IL-4 promotes the production of anti-inflammatory cytokine IL-1ra
137-141
. In a 
population-based prospective genetic study, IL-4 gene polymorphism was found to be a strong 
predictor for incident stroke
142
. Serum levels of IL-4 have been demonstrated to be signiﬁcantly 
elevated in patients at the acute stage of cerebral infarction
143
. Hence, IL-4 may provide a 
negative feedback to counterbalance the production of pro-inflammatory cytokines in ischemic 
stroke. However, IL-4 levels were not found to differ in first-ever acute ischemic stroke patients 
with or without deterioration
144
.  
IL-5 is an anti-inflammatory cytokine predominantly produced by T cells, and by eosinophils and 
mast cells to a less extent. It is a key contributor in inflammatory diseases such as asthma and 
allergic rhinitis. Serum IL-5 levels were negatively correlated with carotid intima-media 
thickness
145
. Also, IL-5 was found to limit formation of foam cells in atherosclerotic lesions 





which inhibits oxidized LDL uptake by macrophages
145
. In addition, genetic polymorphism of the 
α subunit of IL-5 receptor was found to be independently associated with incidence of first-ever 
ischemic stroke in a prospective analysis of Chinese patients with type II diabetes
146
.     
IL-13 is produced by activated T cells, and acts as a potent functional modulator of monocytes 
and B-cells. IL-13 can reduce the production of TNF, IL-1, and IL-8 by monocytes
147, 148
. IL-13 
levels were higher in the sera of patients with peripheral artery disease
149
. The 4045C/T 
polymorphism of IL-13 gene has been reported to be associated with the risk of ischemic stroke 
in the Westphalian study
150
. 
1.2.7 Growth factors 
Both the subsidence of post-ischemic inflammation and the release of a variety of growth factors 
by immune cells, neurons, and astrocytes facilitate post-ischemic brain repair
130, 151, 152
. The 
growth factors help to sustain a favorable environment for important processes involved in brain 
repair including neurogenesis, angiogenesis, and extracellular matrix remodeling
153-155
. Among 
these processes, angiogenesis, formation of new blood vessels, has received much attention as an 
important element in neuronal re-organization and stroke recovery
156
. It has been shown that 
revascularization processes occurred in rat brains after MCAO
157
. Likewise, capillary density was 
found to be increased in the penumbra of postmortem brains of patients who survived for weeks 
after ischemic stroke, and capillary density also correlated with survival time
158, 159
. Therefore, 
growth factors may improve medium-to-long term recovery of stroke patients through increasing 
collateral blood flow, and hence may serve as potential therapeutic targets
156
. Also, growth factors 
may confer additional benefits to stroke recovery through their anti-inflammatory and anti-
apoptotic properties
160
.      
Platelet derived growth factor (PDGF) is a dimeric glycoprotein composed of two A (-AA), two 





AA, possess angiogenic effects
161
 through promoting endothelial and neuroepithelial cell 
migration and proliferation, endothelial cell-pericyte interaction
162
, and blood vessel maturation
163, 
164
. PDGF-B chain is upregulated in the neurons and macrophages in rat brains after cerebral 
ischemia, and PDGF-B induces formation of capillaries, thus increasing microcirculation in 
mice
165, 166
. Prolonged intracerebral infusion of PDGF-BB for 7 to 14 days resulted in reduced 
infarct size in rats undergone transient MCAO
167
. Clinically, PDGF-B chain was found to be 
upregulated in postmortem brains of patients who died after cerebral ischemia, and PDGF-BB 
was reported to be elevated in the plasma of tPA-treated patients compared with normal 
controls
167, 168
. In addition, serum PDGF levels were found to be lower in patients with 
symptomatic carotid disease at risk of plaque instability, compared with asymptomatic patients, 
suggesting that locally released PDGF may lead to plague instability
169
.         
Vascular endothelial growth factor (VEGF), belonging to a family of heparin-binding growth 
factors, is one of the most important angiogenic factors
170
. It is also involved in various processes 
including capillary regulation, neuroprotection, inflammation, wound healing, and repair
160
. 
VEGF is ubiquitously expressed in the brain, mainly by epithelial cells, and also by astrocytes 
and neurons to a less extent
171, 172
. VEGF is induced in the penumbra region under various 
hypoxic conditions
173
, where it may exert protective effects on the damaged cerebral tissue. Mice 
overexpressing VEGF exhibited higher vessel density, enhanced angiogenesis, reduced infarct 
size, and better clinical outcome after MCAO, without increasing cerebral blood flow
174-176
. It has 
been hypothesized that VEGF exerts bi-phasic effects after cerebral ischemia. At the acute stage, 
VEGF may act in combination with angiopoietin-2 to exacerbate ischemic injury through 
increasing the permeability of the BBB and thus leading to edema formation and hemorrhagic 
transformation
177
; whereas after the acute stage (> 48 hours), effects of VEGF are positive 
through promoting angiogenesis and improving functional outcome
176
. Clinically, VEGF levels 
were negatively associated with 10-year coronary heart disease and stroke risk
178





Granulocyte macrophage colony-stimulating factor (GM-CSF) is produced by lymphocytes, 
macrophages, neutrophils, and endothelial cells
179
. It functions to stimulate the survival, 
differentiation, and proliferation of immune cells and enhance neuronal differentiation in adult 
stem cells
180
. Injection of GM-CSF has been shown to reduce infarct size and improve 
neurological outcomes in both mouse and rat stroke models
181
. Both in vitro and in vivo 
experiments have demonstrated that GM-CSF can regulate the expression of anti-apoptotic 
molecules (Bcl-2, Bax, and caspase 3), thereby reducing neuronal apoptosis
182, 183
. Furthermore, 
GM-CSF has been reported to promote collateral proliferation (arteriogenesis) at the circle of 
Willis, posterior cerebral artery, intraparenchymal and leptomeningeal vessels
184, 185
. Clinically, 
GM-CSF levels have been found to be elevated in the plasma of acute stroke patients; however, 
no association was found between GM-CSF levels and neurological outcome
186
.  
Macrophage colony-stimulating factor (M-CSF) promotes the production of IL-6 and granulocyte 
colony-stimulating factor (G-CSF), thereby selectively stimulating the proliferation and 
differentiation of monocytes, granulocytes, and platelets. In vitro, M-CSF has been shown to be 
neuroprotective and inhibit neuronal apoptosis due to excitotoxicity
187
, and administration of 
recombinant M-CSF promoted neuronal survival and reduced infarct size in mice
188
. Nevertheless, 
since M-CSF-deficient mice displayed decreased frequency of atherosclerosis, M-CSF has also 
been hypothesized to play a role in the progression of atherosclerosis
189, 190
. Under clinical setting, 
serum levels of M-CSF were reported to be increased in patients with a history of cerebral 




Leukemia inhibitory factor (LIF) belongs to the IL-6 class cytokine family. Within the nervous 
system, under normal conditions, LIF expression is maintained at very low levels; however, LIF 
is released by neurons and astrocytes in the peri-ischemic region following ischemic onset
192
. 





the direct targets of LIF action
193
. In vivo, prolonged exposure to LIF has been shown to promote 
proliferation and self-renewal of neural stem cells (NSCs), hence regeneration of the 
subventricular zone in mice192. In addition, LIF has been found to be associated with neurogenesis 
and differentiation of NSCs after CNS injury
194, 195
. Injecting LIF into the ischemic brain has been 




1.3 Vascular cognitive impairment (VCI) 
VCI is common after stroke, and is clinically heterogeneous: VCI can be categorized as vascular 
dementia (VaD), cognitive impairment no dementia (CIND), and mixed dementia, in which 
pathological features of more than one type of dementia are simultaneously present
197
. Post-stroke 
dementia has a prevalence ranging from 14-32%, while incidence of dementia rises from 20% at 
3 months to 33% at 5 years after stroke onset
198, 199
. VCI can affect any cognitive domain, but 
tends to affect executive function most commonly
200
. Risk factors for VCI include age, low 
education, prior stroke, and pre-existing neurodegenerative diseases
201-203
. Vascular risk factors, 
such as hypertension, diabetes, hyperlipidemia, and smoking may also predict VCI; however, it 
may be the number of vascular risk factors, as opposed to any individual factor, that may be 
predictive of VCI
201
. The pathophysiology of VCI may be subdivided into large vessel disease 
and small vessel disease. Large vessel disease-induced VCI can be attributed to a single strategic 
infarct or cumulative effects of several cortical infarcts with different sizes and numbers
204
. Small 
vessel disease, on the other hand, includes subcortical ischemic vascular disease, which may be 
caused by small vessel infarct or ischemia within the cerebral white matter, and non-infarct 
ischemic changes and atrophy
205
.  
A growing body of literature indicates that inﬂammation is an important mechanism underlying 
dementia and cognitive decline. Inﬂammation has been implicated in the neuropathology leading 





is believed to be mediated by microglial cells and promoted by cytokines and chemokines
206
. 
Furthermore, numerous inflammatory mediators including complement factors, APPs, 
chemokines (MCP-1 and IP-10), chemokine receptors, Nitrous Oxide Systems (NOS) and 
cyclooxygenase (COX), and inflammatory cytokines (IL-1, TNF-α, and IL-6) have been found in 
brains of AD patients
207
. Levels of IL-1, TNF-α, IL-6, and CRP are elevated in the CSF or 
plasma/serum of AD patients
208-210
. Serum TRAIL levels negatively correlated with MMSE 
scores in AD patients
211
. Moreover, PDGF-BB was previously identified as a plasma biomarker 
for AD
212
. Likewise, there appears to be an association between inflammatory markers and VCI. 
It has been hypothesized that local hypoxia induces expression of hypoxia-sensing molecules 
such as hypoxia inducing factor-1α, which may trigger inflammation213. Alternatively, 
inflammation may be triggered by the need to repair the blood vessels damaged due to 
hypertension or diabetes mellitus
213
. Astrocytes and microglia are activated to contribute to the 
repair process, which in turn triggers inflammatory responses.  
Various studies have implicated inflammation in VCI. Inflammatory responses were found at 
regions with demyelination around the blood vessels in VCI patients
214
. MMPs, which have been 
shown to cause demyelination
215, 216
, are found in the immune cells, activated microglia, 
astrocytes, and are increased in the CSF in VCI patients
217, 218
, which produce various deleterious 
molecules including ROS, cytokine, and proteases. In addition, in VCI patients with diabetes 
mellitus, the integrity of the BBB is compromised, resulting in leakage of serum proteins such as 
albumin into the brain
219, 220
, thus a higher CSF-albumin index. IL-2 secretion is elevated in VaD, 
which may occur in response to increasing neuronal damage and therefore reflect the severity of 
dementia
221
. Higher levels of CRP were associated with lower post stroke MMSE score
222
, 
progression of white matter lesions, and incident lacunar infarcts
223
. VEGF improved cognitive 








1.4 Prognosis and biomarker 
Accurate and reliable predictions of outcome (including cognitive outcome) after ischemic stroke 
are of importance under both clinical and research settings. Clinically, prognosis can help to: a) 
target patients with poor prognosis (for example, patients with poor prognosis may be given more 
efficacious but potentially dangerous therapies such as tissue plasminogen activator (tPA), 
whereas patients with good prognosis may be given more conservative therapies such as 
antiplatelets or other drugs)
225
; b) provide more accurate information to patients and their family 
members
225
; c) improve rehabilitation and discharge planning. In research, prognosis can help to: 
a) optimize patient stratification according to baseline severity in clinical trials; b) adjust for 
differences in baseline risk in statistical analysis for clinical trials
226
; c) correct for baseline 
differences in risk for meta-analyses of various cohorts of patients
227, 228
.   
Thus far, prognostic values of a number of factors such as demographics, social factors, past 
medical history, medications, details of stroke, general clinical examination, neurological 
examination, CT/MRI imaging have been evaluated in various clinical studies in stroke patients. 
Currently, the best validated clinical prognostic models include the six simple variable (SSV) 
model (age, living alone before stroke, mRS ≤ 2 before stroke, normal Glasgow coma scale, able 
to lift arms, and able to walk), model based on conscious level and urinary continence, and 
informal clinical predictions
229
. Nevertheless, these prognostic models are not accurate enough 
for prognosis in individual stroke patients. Similarly, prognosis for VCI is less mature than for 
AD and has not yet identiﬁed candidates that are ready for standardization and widespread 
application. Accordingly, there is a need to find components that may improve the prognostic 
power of current prognostic models.  
Recent advances in biomarker discovery have raised new opportunities for improving the quality 
of stroke prognosis. A biomarker, by definition, is a substance evaluated as an indicator of normal 





intervention, which can be objectively measured
230
. The prognostic value of blood biomarkers of 
the pathological processes implicated in ischemic stroke, such as inflammation, hemostasis, 
neuronal injury, and cardiac dysfuncion, has received much attention. A recent systemic review 
on blood markers for the prognosis of ischemic stroke reported that molecules such as 
adiponectin, brain natriuretic peptide, CRP, ICAM, glutamate, homocystein, insulin-like growth 
factor, MMP-9, platelet activator inhibitor, tau, and thrombomodulin have been found to be 
associated with outcome in most studies
231
. As to cognitive outcomes, higher fibrinogen
232
 and 
combination of high IL-6 and CRP
233
 have been reported to be associated with a higher risk of 
VaD. These evidences suggest the potential of blood markers, perhaps a combination of several 




1.5 Objective of the thesis 
Given the importance of inflammatory responses in ischemic stroke and VCI, it is of interest to 
evaluate the prognostic values of circulating levels of inflammatory markers for stroke outcomes. 
Many previous studies on the association between inflammatory markers and stroke outcomes 
were conducted in non-selected patients at the acute stage (< 24 hours) with a wide range of 
stroke severities. Nonetheless, levels of a number of inflammatory markers such as CRP, 
sVCAM-1, and sICAM-1 are strongly associated with stroke severity at the acute stage, probably 
proportionate to the extent of initial cerebral injury, and stroke severity itself is a strong predictor 
for outcomes
49, 235
. It is therefore conceivable that previous studies are confounded by stroke 
severity. Accordingly, the prognostic value of inflammatory markers needs to be assessed in a 
cohort of stroke patients with homogeneous severities. In addition, inflammatory marker levels 
may be elevated dramatically at the acute stage, which reflects a state of acute inflammatory 
condition and may greatly deviate from the basal inflammatory status of the patients. Hence, 





of the inflammatory status of a patient, may provide more accurate information for predicting 
long-term outcomes.  
Therefore, the present thesis investigated the associations between 24 inflammatory markers and 
stroke outcomes in a cohort of non-disabled stroke patients at the convalescent stage, who were 
followed up for up to 5 years. The primary endpoints investigated include death, recurrent 
vascular events, and dependency, while the secondary endpoints include incident dementia and 
significant cognitive decline. The 24 markers were selected based on mechanisms known to play 
key roles in the inflammatory responses elicited by ischemic stroke: a) cellular adhesion 
molecules (sVCAM-1 and sICAM-1), b) chemokines (MCP-1, RANTES, and MIG), c) pro-
inflammatory cytokines (IL-1α, IL-2, IL-12(p40), IL-15, IL-16, IL-17, IFN-γ, and MIF), d) acute-
phase proteins (CRP), e) apoptotic stimuli (TRAIL), f) anti-inflammatory cytokines (IL-1ra, IL-4, 
IL-5, and IL-13), and g) growth factors (PDGF-AB/BB, VEGF, GM-CSF, M-CSF, and LIF).  
The hypothesis of this thesis is that higher serum levels of cellular adhesion molecules, 
chemokines, pro-inflammatory cytokines, acute-phase proteins, and apoptotic stimuli are 
associated with poor prognosis, whereas higher serum levels of anti-inflammatory cytokines and 






2. METHODS AND MATERIALS 
2.1 Patient population 
All patients with recent transient ischemic attacks (TIA) or minor ischemic strokes seen in the 
Singapore General Hospital between 1999 and 2005 were screened for eligibility for the 
European Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT)
236
. The recruited 
patients were within 6 months of a transient ischemic attack (TIA) (including transient monocular 
blindness) or non-disabling ischemic stroke (grade ≤ 3 on the modified Rankin scale (mRS)) of 
presumed arterial origin. Exclusion criteria were a possible cardiac cause of cerebral ischemia 
(any occurrence of atrial fibrillation, cardiac valve disease, or myocardial infarction in the 
preceding month), high-grade caratid stenosis requiring surgery, moderate or severe leukoaraiosis, 
intracranial haemorrhage, limited life expectancy (weeks or months) due to any malignant disease, 
known indication or contraindication for aspirin or dipyridamole, expected poor compliance with 
therapy, anaemia, polycythemia, thrombocytosis, thrombocytopenia or severe hypertension, and 
age above 75 years. Patients recruited into ESPRIT were eligible for the cognitive substudy 
(ESPRIT-Cog) with the following additional exclusion criteria: confusion, severe aphasia 
(expressive or receptive), major psychoses diagnosed according to DSM-IV criteria, or dominant 
upper limb paralysis.  
The patients were informed about the background and procedures of the study, and written 
informed consents were obtained either from the patients or legal guardians. The study protocol 
was approved by Singapore General Hospital’s Institutional Review Board and Ethics Committee. 
The ESPRIT Trial was registered under www.clinicaltrials.gov with the unique identifier 
NCT00161070. 
2.2 Baseline data 





Information pertaining to demographics and risk factors for vascular diseases or cognitive decline, 
which included age, gender, race, education, stroke subtype, previous vascular events, diabetes 
mellitus, hypertension, hyperlipidemia, smoking status, and baseline mRS score, was obtained 
verbally from the patient and confirmed with hospital records. Stroke subtype was classified 
according to the Oxfordshire Community Stroke Project (OCSP) as total anterior circulation 
infarct (TACI), partial anterior circulation infarct (PACI), posterior circulation infarct (POCI), or 
lacunar infarct (LACI)
237
. A previous vascular event was defined by any past history of ischemic 
heart disease, peripheral artery disease, ischemic stroke, angina pectoris, and myocardial 
infarction. 
2.2.2 Cognitive assessments 
Baseline cognitive assessments were administered to patients consenting to the ESPRIT-cog 
substudy 3 to 4 months after the qualifying events. Both the mini-mental state examination 
(MMSE) and a six-domain neuropsychological test battery previously validated locally were 
administered to the patients in their habitual languages (English, Malay, Mandarin, or Chinese 
dialects)
238, 239





, and Auditory Detection
241










, and Maze Task
246
; and Visuoconstruction, as 
defined by Wechsler Memory Scale–Revised (WMS-R) subtest Visual Reproduction Copy task240, 
Clock Drawing
247
, and Wechsler Adult Intelligence Scale–Revised (WAIS-R) Block Design 
subtest
248
. The memory domains were Verbal Memory, as defined by Word List Recall
249
 
(Immediate, Delayed, and Delayed Recognition) and Story Recall
240
 (Immediate and Delayed); 
and Visual Memory, as defined by Picture Recall
240
 (Immediate, Delayed, and Delayed 
Recognition) and WMS-R Visual Reproduction
240
. The entire battery took under an hour and a 





Dementia was diagnosed according to the DSM-IV criteria
250
. Computed tomography, magnetic 
resonance imaging and magnetic resonance angiography were reviewed as part of the diagnostic 
process. The cognitive status of individuals who did not fulfil the criteria for dementia was 
categorized as Cognitive Impairment No Dementia (CIND) or No Cognitive Impairment (NCI)
251
. 
CIND was defined as impairment in at least one domain of the neuropsychological test battery, 
and was further subcategorized according to severity into CIND-mild (1-2 domains impaired) or 
CIND-moderate (3-6 domains impaired)
252
. 
2.2.3 Determination of inflammatory markers 
Fasting blood samples were drawn at baseline and processed immediately. Samples were 
centrifuged at 2000G for 10 minutes at 4°C, aliquoted into smaller amounts to prevent freeze-
thaw cycles and then stored at –80⁰C until use.  
All inflammatory markers were measured from serum using the xMAP multiplexing technology 
(Luminex, USA). Tiny beads, called microspheres, are color-coated into 500 distinct sets. Each 
bead set is coated with an antibody specific to a particular analyte, allowing the capture and 
detection of specific analytes from a sample. Inside the laser analyzer, a light source excites the 
internal dyes that identify each microsphere particle, and also any reporter dye captured during 
the assay. Using this process, xMAP Technology allows multiplexing of up to 500 unique 
analytes within a single sample.  
Antibody-immobilized beads, high-concentration and low-concentration quality controls (QC), 
and assay standard were reconstituted. The 96-well plate was washed with 200μl of assay buffer 
or wash buffer for 10 minutes at room temperature (RT, 25⁰C) before being vacuum-dried. 25μl 
of assay buffer, assay standards, QCs, neat or diluted samples, and assay beads were added into 
respective wells according to the given protocol. The plate was then incubated with agitation for 1 





200μl of wash buffer and incubated with 25μl of detection antibodies for 30 minutes or 1 hour at 
RT with agitation. Afterwards, the samples were incubated with 25 Streptavidin-PE for 30 
minutes at RT with agitation. Finally, the plate was vacuum-washed twice with 200μl of wash 
buffer, and incubated with 150μl of sheath fluid for 5 minutes before reading. The results were 
read using xPONENT software (Luminex, USA; version 3.1). Standard curves were fitted using 
the Brendan’s Five-Parameter logistic curve provided in Milliplex analyst software (Millipore, 
USA; version 3.5). All samples were measured in duplicate. 
sVCAM-1, sICAM-1, and MIF were assayed by MILLIPLEXMAP Human Sepsis/Apoptosis Panel 
(Millipore, USA); CRP by MILLIPLEX MAP Human Cardiovascular Disease Panel 2 (Millipore, 
USA); IL-1α, IL-1ra, IL-2, IL-4, IL-5, IL-12 (p40), IL-13, IL-15, IL-17, GM-CSF, IFN-γ, MCP-1, 
PDGF-AB/BB, RANTES, and VEGF by MILLIPLEX MAP Human Cytokine/Chemokine Panel 1 
(Millipore, USA); IL-16, LIF, and TRAIL by MILLIPLEX MAP Human Cytokine/Chemokine 
Panel 2 (Millipore, USA); M-CSF and MIG/CXCL9 by MILLIPLEX MAP Human 
Cytokine/Chemokine Panel 3 (Millipore, USA). 
The standard curve range was 61-250000 pg/mL for sVCAM-1 and sICAM-1; 12-50000 pg/mL 
for MIF; 80-250000 pg/mL for CRP; 3.2-10000 pg/mL for Human Cytokine/Chemokine Panel 1; 
1.0-100000 pg/mL for Human Cytokine/Chemokine Panel 2; 2-200000 pg/mL for Human 
Cytokine/Chemokine Panel 3.  
The intra-assay coefficients of variation of MILLIPLEXMAP Human Sepsis/Apoptosis Panel 
ranged from 6.4% to 14.2%; MILLIPLEX MAP Human Cardiovascular Disease Panel 2 was 3%; 
MILLIPLEX MAP Human Cytokine/Chemokine Panel 1 from 4.6% to 13.8%; MILLIPLEX MAP 
Human Cytokine/Chemokine Panel 2 from 5.6% to 13.8%; MILLIPLEX MAP Human 
Cytokine/Chemokine Panel 3 from 3% to 7%. The inter-assay coefficients of variation of 





Human Cytokine/Chemokine Panel 1 from 3.7% to 17.2%; MILLIPLEX MAP Human 
Cytokine/Chemokine Panel 2 from 9.3% to 19.8%; MILLIPLEX MAP Human 
Cytokine/Chemokine Panel 3 from 3% to 8%. 
2.3 Outcome measurements at follow-up 
2.3.1 Vascular outcomes 
The patients were followed at six-monthly intervals for up to five years. Occurrence of a recurrent 
vascular event was ascertained by patient interview and verified with hospital records. A 
recurrent vascular event was defined as the occurrence of stroke, peripheral artery disease, 
intracranial bleed, any cardiac ischemia (stable and unstable angina, myocardial infarctions) or 
death from any of the above. Dependency was measured by dichotomizing the mRS
253
 (0 = no 
symptoms, 1 = symptoms, no disability, 2 = slight disability, 3 = moderate disability, 4 = 
moderately severe disability, 5 = severe disability, 6 = death) into good (0-2) versus poor (3-6) 
outcomes. For patients whose baseline mRS grade was 3, dependency was determined if their 
grades declined to 3 or greater. Death events were confirmed with hospital and/or death registry 
records at the end of the study. 
2.3.2 Cognitive outcomes 
Dementia diagnoses were made at weekly consensus meetings. The neuropsychological test 
battery was administered to the patients annually for up to 5 years
239
. Significant cognitive 
decline was defined as one of the following conditions: a) a decline from NCI or CIND-mild to 
CIND-moderate, or b) a conversion to dementia. 
2.4 Statistical analysis 
As levels of the inflammatory markers were not normally distributed, Spearman’s correlation, 
Mann-Whitney U test, and Kruskal-Wallis tests were performed as appropriate to investigate the 





significantly associated with inflammatory marker levels were tested in ordered ordinal regression, 
which is a type of regression analysis for predicting an ordinal variable whose value exists on an 
arbitrary scale where only the relative ordering between different values is significant, to 
determine independent predictors of inflammatory marker levels. Additionally, ordered ordinal 
regressions were performed to determine predictors for baseline MMSE score. The Mann-
Whitney U test was used to compare inflammatory marker levels in patients who had an outcome 
event against those who remained free of outcome events.  
Cox regression, which is a type of survival model relating the time passed before an outcome 
event occurs to covariates that may be associated with the outcome, was used to determine 
predictors of death, recurrent vascular events, dependency, and incident dementia. Logistic 
regression, which is a type of regression analysis for predicting a binomial variable, was 
performed to determine predictors of significant cognitive decline. To begin with, inflammatory 
markers and baseline covariates were tested individually in univariate Cox and logistic 
regressions to determine which variables were predictive of each investigated outcome. 
Significant predictors at the univariate stage were entered together in multivariate regression 
models to test for independent predictors of each outcome. Afterwards, multivariate Cox and 
logistic regressions were performed in 2 models. In model 1, independent predictors for outcome 
were controlled for. In model 2, in addition to covariates in model 1, covariates previously 
reported to be associated with inflammatory marker levels or outcome were controlled for. Effect 
modification by delay to blood draw (dichotomized at day 7 and day 60) on the association 
between inflammatory marker levels and outcomes was also examined in regression analyses.  
Due to skewed distributions, levels of sVCAM-1, sICAM-1, MIF, CRP, VEGF, PDGF-AB/BB, 
RANTES, TRAIL, and MIG were transformed as appropriate, and the z scores of the transformed 
levels were entered into the regression models continuously as per SD increase (approximately 





30% of total (MCP-1, IFN-γ, IL-17, and IL-16), continuous analyses were not possible. Therefore 
the patient population was stratified according to tertiles of marker levels for regression analyses. 
GM-CSF was undetectable in more than 30% but less than 50% of total patients, hence the 
population was dichotomized at the median level of GM-CSF for regression analyses. Analytes 
undetectable in more than half of total patients were excluded from analysis.  
Significance was established with a 95% confidence interval (CI) exclusive of one for Cox and 
logistic regression analyses, and with a two-tailed p-value less than 0.05 for all the other 









3.1 Baseline characteristics of patient population 
Of the 458 patients enrolled at the Singapore General Hospital site of the ESPRIT study, 320 
patients had serum available for analysis, of which 9 were lost to follow-up. Hence, data of 311 
patients are presented for vascular outcomes (mean age 60±12 years, 36% female; median delay 
to blood draw, 47 days). Patients not included in analysis were more likely to have diabetes 
mellitus (48% versus 36%; p=0.01) and previous vascular events (36% versus 26%; p=0.03), but 
less likely to have hyperlipidemia (35% versus 47%; p=0.02). Of these 311 patients, 8 declined 
the ESPRIT-cog substudy, 11 were demented at baseline and 24 had less than 1 year of cognitive 
follow-up, leaving 268 patients for whom cognitive outcomes were available (mean age 60±11 
years, 33% female; median delay to blood draw, 45 days). The patient population is summarized 
in Figure 2. Baseline characteristics of the patient population are presented in Table 1. 






Table 1. Baseline characteristics of patient population 
Demographics and risk factors n (%) 
Age, y, mean (SD, range) 60 (12, 22-88) 
Women 111 (36) 
Days to blood draw, median (IQR) 47 (14-93) 
Education  
     Nil/Primary 183 (60) 
     Secondary/Tertiary 120 (40) 
Hyperlipidemia 147 (47) 
Diabetes mellitus 112 (36) 
Hypertension  227 (73) 
Previous vascular events 81 (26) 
Smoking 112 (36) 
Treatment  
     Aspirin 158 (51) 
     Aspirin + Dipyridamole 134 (43) 
     Anticoagulant 19 (6) 
Race   
     Chinese  264 (85) 
     Malay 20 (6) 
     Indian 27 (9) 
Stroke subtype  
     TIA 57 (18) 
     POCI/LACI 226 (73) 
     TACI/PACI 28 (9) 
Baseline MMSE score, points, median (IQR) 27 (24-29) 
Inflammatory marker levels Median (IQR) 
sVCAM-1, ng/mL 422 (363-507) 
sICAM-1, ng/mL 96 (76-126) 
MIF, ng/mL 1.4 (0.7-2.3) 
CRP, mg/L 3.3 (1.4-6.7) 
GM-CSF, pg/mL 0.2 (0.01-1.4) 
IFN-γ, pg/mL 1.5 (0.3-4.5) 
IL-17, pg/mL 0.5 (0.2-1.6) 
MCP-1, pg/mL 346 (269-437) 
VEGF, pg/mL 251 (127-441) 
PDGF-AB/BB, ng/mL 51 (39-65) 
RANTES, ng/mL 49 (36-67) 
IL-16, pg/mL 29 (13-64) 
TRAIL, pg/mL 50 (36-70) 
MIG, ng/mL 1.2 (0.8-1.9) 
SD = standard deviation, IQR = interquartile range, TIA = transient ischemic attack, POCI = 





PACI = partial anterior circulation infarct, MMSE = mini-mental state examination, sVCAM-1 = 
soluble vascular cell adhesion molecule-1, sICAM-1 = soluble intercellular adhesion molecule-1, 
MIF = macrophage migration inhibitory factor, CRP = C-reactive protein, GM-CSF = 
Granulocyte macrophage colony-stimulating factor, IFN-γ = interferon-gamma, IL-17 = 
interleukin-17, MCP-1 = monocyte chemotactic protein-1, VEGF = vascular endothelial growth 
factor, PDGF-AB/BB = platelet derived growth factor-AB/BB, RANTES = regulated upon 
activation, normal T-cell expressed, and secreted, IL-16 = inteleukin-16, TRAIL = TNF-related 
apoptosis-inducing ligand, and MIG = monokine induced by gamma. 
3.2 Outcomes of patient population 
During the course of study (median, 3 years), a total of 18 (6%) patients died (4 vascular deaths), 
35 (11%) patients experienced recurrent vascular events (24 ischemic strokes, 5 myocardial 
ischemia, and 6 intracerebral hemorrhages), and 25 (8%) patients became dependent. 
During the course of cognitive follow-up (median, 3 years), a total of 12 (4%) patients converted 
to dementia, and 34 (13%) patients were determined to have experienced a significant cognitive 
decline (22 conversions to CIND-moderate and 12 conversions to dementia). 
3.3 Regression analyses predicting outcomes  
3.3.1 Cellular adhesion molecules 
3.3.1.1 sVCAM-1 
Patients who were older, less educated, with diabetes mellitus and hypertension had significantly 
higher levels of sVCAM-1. In addition, sVCAM-1 levels weakly and negatively correlated with 
baseline MMSE score (Spearman’s ρ, -0.29; p<0.001) (Figure 3). Diabetes mellitus (p<0.0001) 
was independently associated with higher sVCAM-1 levels. In addition, adjusting for gender, age, 
baseline mRS score, race, education, diabetes mellitus, hypertension, and stroke subtype, 
sVCAM-1 levels were independently associated with baseline MMSE score (p=0.03). sVCAM-1 
was not associated with delay to blood draw or treatment.  
Patients who died had higher median sVCAM-1 levels (554 ng/mL) compared to those who 
survived (418 ng/mL; p=0.0001) (Figure 4A). Patients who had a recurrent vascular event had 





p=0.02) (Figure 4B). Results of Cox regression analyses predicting vascular outcomes are 
summarized in Table 2. sVCAM-1 was independently associated with death (HR per SD increase 
of square-root transformed values, 1.85; 95% CI, 1.07-3.19). Also, sVCAM-1 was independently 
associated with recurrent vascular events in model 1, and exhibited a trend towards significance 
in model 2. In sub-analysis for specific mechanistic outcomes, sVCAM-1 was independently 
associated with recurrent ischemic stroke (HR per SD increase of square-root transformed values, 
1.62; 95% CI, 1.08-2.41). sVCAM-1 was not predictive of dependency. There was no effect 
modification by delay to blood draw on the associations of sVCAM-1 levels with any vascular 
outcome investigated. 
Median sVCAM-1 levels were higher in patients who converted to dementia (508 ng/mL) 
compared with those who did not (418 ng/mL; p=0.02), and in patients who had a significant 
cognitive decline (472 ng/mL) compared with those who did not (418 ng/mL; p=0.02). Results of 
Cox regression and logistic regressions predicting cognitive outcomes are summarized in Table 3. 
sVCAM-1 was not an independent predictor for incident dementia or significant cognitive decline. 
There was no effect modification by delay to blood draw on the associations of sVCAM-1 levels 
with any cognitive outcome investigated.  
3.3.1.2 sICAM-1 
Patients who were less educated and smokers had significantly higher levels of sICAM-1, 
whereas sICAM-1 levels did not correlate with baseline MMSE score (Spearman’s ρ, -0.10; 
p=0.10). sICAM-1 was not associated with delay to blood draw or treatment. There was a weak 
but significant correlation between sVCAM-1 and sICAM-1 (Spearman’s ρ, 0.20; p=0.0005).   
Levels of sICAM-1 did not differ between patients who had an outcome event compared with 
those who remained free of outcome event. sICAM-1 was not predictive of any outcome 





Figure 3. Associations of sVCAM-1 levels with baseline MMSE score 
 
MMSE = mini-mental state examination and sVCAM-1 = soluble vascular cell adhesion 
molecule-1. 






p = 0.0001 






B. Recurrent vascular events 
 
sVCAM-1 = soluble vascular cellular adhesion molecule-1. 
Table 2. Cox regression analysis of the association of sCAM levels with death, recurrent 
vascular events, and dependency 
 HR per SD increase of sCAM levels (95% CI) 
Death Recurrent vascular 
events (composite 
endpoint of recurrent 





from recurrent IS) 
Dependency 
Square-root transformed sVCAM-1 
Univariate  2.20 (1.49-3.24) 1.45 (1.07-1.95) 1.68 (1.20-2.36) 1.32 (0.92-1.90) 
Multivariate     
     Model 1 2.10 (1.39-3.17) 1.40 (1.04-1.89) 1.66 (1.18-2.34)  
     Model 2 1.85 (1.07-3.19) 1.35 (0.97-1.88) 1.62 (1.08-2.41)  
Inverse transformed sICAM-1 
Univariate  1.16 (0.74-1.84) 1.13 (0.81-1.59) 1.41 (0.96-2.07) 1.04 (0.70-1.55) 
Death: model 1 adjusted for diabetes mellitus; model 2 adjusted for age, race, baseline MMSE 
score, previous vascular events, diabetes mellitus, smoking, stroke subtype, baseline mRS score, 
gender, and hyperlipidemia. Recurrent vascular events and recurrent stroke: model 1 adjusted for 
treatment; model 2 adjusted for treatment, age, gender, baseline MMSE score, previous vascular 
events, diabetes mellitus, hypertension, stroke subtype, hyperlipidemia, and smoking.  
HR=hazard ratio, SD=standard deviation, sCAM=soluble cellular adhesion molecule, 
CI=confidence interval, sVCAM-1=soluble vascular cell adhesion molecule-1, sICAM-1=soluble 
intercellular adhesion molecule-1, IS=ischemic stroke, MI=myocardial infarction, and 
ICH=intracerebral hemorrhage. 





Table 3. Cox and logistic regression analysis of the association of CAM levels with incident 
dementia and significant cognitive decline 
 HR per SD increase of 
sCAM levels (95% CI) 
OR per SD increase of 
sCAM levels (95% CI) 
Incident dementia Significant cognitive decline 
Square-root transformed sVCAM-1   
Univariate  1.81 (1.11-2.93) 1.52 (1.06-2.17) 
Multivariate   
     Model 1 1.25 (0.67-2.34) 1.11 (0.72-1.71) 
Inverse transformed sICAM-1   
Univariate  0.85 (0.48-1.51) 0.93 (0.65-1.33) 
Incident dementia: model 1 adjusted for baseline MMSE score and previous vascular events. 
Significant cognitive decline: model 1 adjusted for baseline MMSE score, previous vascular 
events, and age.   
HR=hazard ratio, SD=standard deviation, sCAM=soluble cellular adhesion molecule, 
CI=confidence interval, sVCAM-1=soluble vascular cell adhesion molecule-1, sICAM-1=soluble 
intercellular adhesion molecule-1, and OR=odds ratio. 
3.3.2 Chemokines 
3.3.2.1 MIG 
Patients who were female (p=0.01), older (p<0.0001), with hypertension (p=0.04), and had less 
education (p=0.0001) were more likely to have higher levels of MIG. Furthermore, levels of MIG 
significantly correlated with baseline MMSE score (Spearman’s ρ= -0.34; p<0.0001) (Figure 5). 
However, after adjusting for gender, age, baseline mRS score, race, education, diabetes mellitus, 
hypertension, and stroke subtype, MIG was no longer significantly associated with baseline 
MMSE score. 
Levels of MIG did not differ between patients who had a vascular outcome event and those who 
remained free of vascular outcome event. Results of Cox regression analyses predicting vascular 
outcomes are summarized in Table 4. MIG was not predictive of any vascular outcome 





Patients who were determined to have significant cognitive decline (2.0 pg/mL) had a higher level 
of MIG compared with those who did not have a significant cognitive decline (1.1 ng/mL) 
(p=0.009) (Figure 6). Results of Cox and logistic regression analyses predicting cognitive 
outcomes are summarized in Table 5. In univariate analysis, a higher level of MIG was 
significantly associated with a higher risk of significant cognitive decline. Nevertheless, after 
adjusting for baseline MMSE score, age, and previous vascular events in multivariate analysis, 
the association was no longer statistically significant. MIG was not predictive of dementia in 
regression analyses.  
3.3.2.2 MCP-1  
Patients who were of Indian ethnicity (p=0.0001) and had less education (p=0.048) were more 
likely to have higher levels of MCP-1. There was a weak but significant correlation between MIG 
and MCP-1 levels (Spearman’s ρ= 0.14; p=0.04).  
Patients who died during the course of study (446 pg/mL) had a higher median level of MCP-1 
compared with those who survived (343 pg/mL) (p=0.02) (Figure 7). In univariate analysis, 
patients in Tertile 2 and Tertile 3 of MCP-1 levels were not at significantly higher risk of death, 
compared with those who were in Tertile 1 (Table 4). MCP-1 was not predictive of recurrent 
vascular events or dependency.  
Levels of MCP-1 were not different between patients who experienced cognitive deterioration 
compared with those who did not. MCP-1 was not predictive of cognitive outcome in regression 
analyses (Table 5). 
3.3.2.3 RANTES 





Levels of RANTES were not different between patients who had an outcome event and those who 
remained free of an outcome event. RANTES was not predictive of any investigated outcome in 
regression analyses (Table 4-5).  
Figure 5. Associations of MIG levels with baseline MMSE score 
 
MMSE = mini-mental state examination and MIG = monokine induced by gamma. 
Table 4. Cox regression analysis of the association of chemokine levels with death, recurrent 
vascular events, and dependency 
 HR per SD increase of chemokine levels (95% CI) 
Death Recurrent vascular events  
(composite endpoint of recurrent 





Univariate  0.91 (0.57-1.45) 0.94 (0.66-1.32) 0.92 (0.62-1.36) 
Inverse square-root transformed MIG 
Univariate  0.66 (0.37-1.18) 0.93 (0.61-1.41) 0.67 (0.39-1.15) 
MCP-1
*
    
Univariate     
     Tertile 1 (ref) 1.00 1.00 1.00 
     Tertile 2      2.26 (0.44-11.6) 0.60 (0.25-1.44) 0.75 (0.28-2.03) 
     Tertile 3 3.82 (0.82-17.7) 0.88 (0.41-1.91) 0.79 (0.30-2.04) 







Due to depletion of serum samples, the sample size 224 for MIG, and 309 for RANTES. 
 
HR=hazard ratio, SD=standard deviation, IS=ischemic stroke, MI=myocardial infarction, 
ICH=intracerebral hemorrhage, RANTES = Regulated upon Activation, Normal T-cell Expressed, 
and Secreted, MIG = Monokine Induced by Gamma, and MCP-1 = Monocyte Chemotactic 
Protein-1. 
Figure 6. Box plots of distributions of MIG levels in patients with and without significant 
cognitive decline 
 
MIG = monokine induced by gamma. 
Table 5. Cox and logistic regression analysis of the association of chemokine levels with 
incident dementia and significant cognitive decline 
 
 HR per SD increase of 
chemokine levels (95% CI) 
OR per SD increase of 
chemokine levels (95% CI) 
Incident dementia Significant cognitive decline 
Log-RANTES
*
   
Univariate  1.37 (0.77-2.45) 1.21 (0.84-1.73) 
Inverse square-root transformed MIG  
Univariate  0.76 (0.39-1.48) 0.55 (0.34-0.88) 
Multivariate    
     Model 1  0.72 (0.40-1.30) 
MCP-1
*
   
Univariate    
     Tertile 1
 
(ref) 1.00 1.00 
     Tertile 2 5.62 (0.68-46.7) 1.48 (0.60-3.69) 





     Tertile 3 4.09 (0.46-36.7) 0.97 (0.35-2.65) 
*
 Due to depletion of serum samples, the sample size was 187 for MIG, and 266 for RANTES. 
Significant cognitive decline: model 1 adjusted for baseline MMSE score, age, and previous 
vascular events. 
 
HR=hazard ratio, SD = Standard Deviation, CI=confidence interval, OR=odds ratio, RANTES = 
Regulated upon Activation, Normal T-cell Expressed, and Secreted, MIG = Monokine Induced 
by Gamma, and MCP-1 = Monocyte Chemotactic Protein-1. 
Figure 7. Box plots of distributions of MCP-1 levels in patients who died and those who 
survived 
  
MCP-1 = Monocyte chemotactic protein-1. 
3.3.3 Pro-inflammatory cytokines 
3.3.3.1 MIF 
Patients who were male (p=0.01) were more likely to have a higher level of MIF. Also, higher 
MIF levels significantly correlated with shorter delay to blood draw (p=0.01).  
Patients who had a recurrent vascular event (1.7 ng/mL) had a higher level of MIF, compared 
with those who remained free of recurrent vascular events (1.3 ng/mL) (p=0.03) (Figure 8). 





Results of Cox regression analyses predicting vascular outcomes are summarized in Table 6. In 
univariate analysis, higher levels of MIF were significantly associated with a higher risk of 
recurrent vascular events; however, after adjusting for treatment in multivariate analysis, the 
association was no longer significant. MIF was not predictive of death or dependency in 
regression analyses.  
MIF levels did not differ between patients who had a cognitive outcome event and those who did 
not have a cognitive outcome event. Results of Cox regression and logistic regressions predicting 
cognitive outcomes are summarized in Table 7. MIF did not predict any cognitive outcome 
investigated. 
3.3.3.2 IL-16 
Patients who were older (p=0.03), had less education (p=0.002), diabetes mellitus (p=0.01), and 
no previous vascular events (p=0.03) were more likely to have higher levels of IL-16. Moreover, 
IL-16 levels significantly correlated with baseline MMSE score (Spearman’s ρ= -0.22; p=0.001) 
(Figure 9). Nevertheless, after adjusting for gender, age, race, education, diabetes mellitus, stroke 
subtype, hypertension, and baseline mRS score, IL-16 was not significantly associated with 
baseline MMSE score. Education, diabetes mellitus, and previous vascular events were 
independently associated with IL-16 levels.  
Patients who died (86 pg/mL) during the course of study had higher median level of IL-16, 
compared with those who survived (28 pg/mL) (p=0.04) (Figure 10A). Patients who became 
dependent (41 pg/mL) had higher levels of IL-16, compared with those who remained 
independent (27 pg/mL) (p=0.03) (Figure 10B). In univariate Cox regression analyses, patients in 
Tertile 3 of IL-16 levels were at a significantly higher risk of dependency, compared with those in 
Tertile 1. In multivariate analysis adjusting for gender (model 1), patients in both Tertile 2 and 





However, after adjusting for gender, education, diabetes mellitus, and previous vascular events 
(model 2), IL-16 was no longer significantly associated with dependency (Table 6). IL-16 did not 
predict death or recurrent vascular events in regression analyses.  
IL-16 levels did not differ between patients who had a cognitive outcome and those who 
remained free of cognitive outcome. In univariate logistic regression analyses, patients in Tertile 
2 of IL-16 levels were at a significantly higher risk of developing significant cognitive decline, 
compared with those in Tertile 1. However, in multivariate analyses adjusting for age, previous 
vascular events, and baseline MMSE score, IL-16 was no longer associated with the risk of 
developing significant cognitive decline (Table 7). IL-16 did not predict incident dementia in 
regression analyses. 
3.3.3.3 IL-17 
Older patients were more likely to have a higher level of IL-17 (p=0.01). Weak but significant 
correlations were also present between IL-17 and IL-16 (Spearman’s ρ=0.19; p=0.005).  
Levels of IL-17 were not different between patients who had an outcome event and those who did 
not. IL-17 did not predict any outcome investigated in regression analyses (Table 6-7). 
3.3.3.4 IFN-γ 
Older patients were more likely to have a higher level of IFN-γ (p=0.001). There was a moderate 
correlation between IL-17 and levels (Spearman’s ρ=0.66; p<0.0001). Weak but significant 
correlations were also present between IFN-γ and IL-16 (Spearman’s ρ=0.17; p=0.01). 
Levels of IFN-γ were not different between patients who had an outcome event and those who did 
not. IFN-γ was not predictive of any outcome investigated in regression analyses (Table 6-7).  
3.3.3.5 IL-1, IL-15, IL-2, and IL-12 





Figure 8. Box plots of distributions of MIF levels in patients with and without recurrent 
vascular events 
 
MIF = macrophage migration inhibitory factor. 
Table 6. Cox regression analysis of the association of pro-inflammatory cytokine levels with 
death, recurrent vascular events, and dependency 
 HR per SD increase of pro-inflammatory cytokine levels (95% CI) 
Death Recurrent vascular events  
(composite endpoint of recurrent 
IS, MI, ICH and vascular death) 
Dependency 
Log-MIF 
Univariate  0.87 (0.55-1.38) 1.42 (1.00-2.02) 0.94 (0.64-1.38) 
Multivariate     




Univariate     
     Tertile 1 (ref) 1.00 1.00 1.00 
     Tertile 2      1.61 (0.45-5.70) 1.09 (0.50-2.38) 0.62 (0.22-1.70) 
     Tertile 3 1.57 (0.44-5.57) 0.75 (0.32-1.78) 0.87 (0.34-2.20) 
IL-16
*
    
Univariate     
     Tertile 1 (ref) 1.00 1.00 1.00 
     Tertile 2      0.19 (0.02-1.60) 2.04 (0.70-5.96) 7.81 (0.99-61.7) 
     Tertile 3 1.97 (0.68-5.67) 2.40 (0.85-6.73) 9.20 (1.18-72.0) 





Multivariate     
     Model 1    
          Tertile 1 (ref)   1.00 
          Tertile 2   8.63 (1.09-68.1) 
          Tertile 3   7.95 (1.02-62.2) 
     Model 2    
          Tertile 1 (ref)   1.00 
          Tertile 2   6.88 (0.84-56.4) 
          Tertile 3   5.56 (0.68-45.7) 
IFN-γ*    
Univariate     
     Tertile 1 (ref) 1.00 1.00 1.00 
     Tertile 2      2.62 (0.70-9.89) 0.97 (0.46-2.03) 1.39 (0.56-3.46) 
     Tertile 3 1.84 (0.44-7.74) 0.45 (0.17-1.17) 0.71 (0.23-2.18) 
* 
Due to depletion of serum samples, the sample size was 287 for IL-17 and IFN-γ, and 293 for 
IL-16. 
 
Recurrent vascular events: model 1 adjusted for treatment. Dependency: model 1 adjusted for 
gender; model 2 adjusted for gender, previous vascular events, education, and diabetes mellitus. 
HR=hazard ratio, SD=standard deviation, IS=ischemic stroke, MI=myocardial infarction, 
ICH=intracerebral hemorrhage, MIF = Macrophage Migration Inhibitory Factor, IL-17 = 
Interleukin-17, IFN-γ = Interferon-gamma, and IL-16 = Interleukin-16.  
Table 7. Cox and logistic regression analysis of the association of pro-inflammatory 
cytokine levels with incident dementia and significant cognitive decline 
 
 HR per SD increase of pro-
inflammatory cytokine 
levels (95% CI) 
OR per SD increase of pro-
inflammatory cytokine 
levels (95% CI) 
Incident dementia Significant cognitive decline 
Log-MIF   




Univariate    
     Tertile 1
 
(ref) 1.00 1.00 
     Tertile 2 0.46 (0.09-2.36) 0.45 (0.17-1.18) 
     Tertile 3 0.93 (0.25-3.45) 0.54 (0.22-1.36) 
IL-16
*
   
Univariate    
     Tertile 1
 
(ref) 1.00 1.00 
     Tertile 2 1.33 (0.30-5.94) 2.81 (1.03-7.72) 
     Tertile 3 1.71 (0.41-7.14) 2.61 (0.94-7.24) 





     Model 1   
          Tertile 1 (ref)  1.00 
          Tertile 2  2.96 (0.95-9.15) 
          Tertile 3  1.83 (0.58-5.74) 
IFN- γ*   
Univariate    
     Tertile 1
 
(ref) 1.00 1.00 
     Tertile 2 2.58 (0.50-13.3) 0.97 (0.40-2.38) 
     Tertile 3 2.59 (0.47-14.2) 0.80 (0.31-2.12) 
*
Due to depletion of serum samples, the sample size was 244 for IL-17 and IFN-γ, and 251 for 
IL-16. 
Significant cognitive decline: model 1 adjusted for age, baseline MMSE score, and previous 
vascular events. 
 
HR=hazard ratio, SD = Standard Deviation, CI=confidence interval, OR=odds ratio, MIF = 
Macrophage Migration Inhibitory Factor, IL-17 = Interleukin-17, IFN-γ = Interferon-gamma, and 
IL-16 = Interleukin-16. 
Figure 9. Associations of IL-16 levels with baseline MMSE score 
 
IL-16 = interleuin-16 
 
 












IL-16 = interleuin-16. 
 
p = 0.04 





3.3.4 Acute-phase proteins 
Patients who were female (p=0.02) and had less education (p=0.03) were more likely to have 
higher levels of CRP.  
CRP level was not different in patients who had an outcome event versus those who did not for 
death (p=0.80), recurrent vascular events (p=0.48), or dependency (p=0.16). Table 8 summarizes 
the results of Cox regression analysis predicting outcomes. In univariate analysis, patients who 
had higher CRP levels did not have increased risk of death, recurrent vascular events, or 
dependency, compared with those with lower CRP levels.  
CRP level was not different in patients who had an outcome event versus those who did not for 
incident dementia (p=0.92) or significant cognitive decline (p=0.92). Table 9 summarizes the 
results of Cox and logistic regression analysis predicting outcomes. In univariate analysis, 
patients who had higher CRP levels did not have increased risk of incident dementia or 
significant cognitive decline, compared with those with lower CRP levels. The delay to blood 
draw did not modify the association between CRP and any outcome measure.  
Table 8. Cox regression analysis of the association of CRP levels with death, recurrent 
vascular events, and dependency 
 HR per SD increase of chemokine levels (95% CI) 
Death Recurrent vascular events  
(composite endpoint of recurrent 
IS, MI, ICH and vascular death) 
Dependency 
Log-CRP 
Univariate  1.07 (0.68-1.70) 0.87 (0.62-1.21) 1.07 (0.72-1.59) 
 
HR=hazard ratio, SD=standard deviation, IS=ischemic stroke, MI=myocardial infarction, 
ICH=intracerebral hemorrhage, and CRP = C-Reactive Protein. 
Table 9. Cox and logistic regression analysis of the association of CRP levels with incident 
dementia and significant cognitive decline 
 HR per SD increase of 
chemokine levels (95% CI) 
OR per SD increase of 





Incident dementia Significant cognitive decline 
Log-CRP   
Univariate  1.00 (0.56-1.79) 0.91 (0.63-1.32) 
 
HR=hazard ratio, SD = Standard Deviation, CI=confidence interval, OR=odds ratio, and CRP = 
C-reactive protein. 
3.3.5 Apoptotic stimuli 
Levels of TRAIL were not associated with any demographic variable or risk factor. 
Levels of TRAIL were not different between patients with a vascular outcome event and those 
without an outcome event. Results of Cox regression predicting vascular outcomes are 
summarized in Table 10. In univariate analysis, a higher level of TRAIL was significantly 
associated with a higher risk of dependency. In multivariate analysis adjusting for gender (model 
1), a higher level of TRAIL significantly associated with higher risk of dependency. However, in 
model 2 adjusting for gender, education, previous vascular events, and diabetes mellitus, TRAIL 
was no longer significantly associated with dependency. TRAIL was not predictive of death or 
recurrent vascular events in regression analyses. 
Levels of TRAIL were not different between patients with a cognitive outcome event and those 
without an outcome event. Results of Cox and logistic regression predicting vascular outcomes 
are summarized in Table 11. In univariate analysis, TRAIL was not significantly associated with 
the risk of any cognitive outcome investigated. 
Table 10. Cox regression analysis of the association of TRAIL with death, recurrent 
vascular events, and dependency 
 HR per SD increase of chemokine levels (95% CI) 
Death Recurrent vascular events  
(composite endpoint of recurrent 





Univariate  1.47 (0.94-2.32) 1.21 (0.84-1.73) 1.50 (1.00-2.25) 
Multivariate     





     Model 2   1.33 (0.91-1.92) 
 
* 
Due to depletion of serum samples, the sample size for TRAIL was 293. 
Dependency: model 1 adjusted for gender; model 2 adjusted for gender, education, previous 
vascular events, and diabetes mellitus.  
HR=hazard ratio, SD=standard deviation, IS=ischemic stroke, MI=myocardial infarction, 
ICH=intracerebral hemorrhage, and TRAIL = TNF-related apoptosis-inducing ligand. 
Table 11. Cox and logistic regression analysis of the association of TRAIL levels with 
incident dementia and significant cognitive decline 
 HR per SD increase of 
chemokine levels (95% CI) 
OR per SD increase of 
chemokine levels (95% CI) 
Incident dementia Significant cognitive decline 
Square-root transformed TRAIL
*
   
Univariate  0.89 (0.50-1.59) 1.05 (0.72-1.52) 
*
Due to depletion of serum samples, the sample size for TRAIL was 251. 
HR=hazard ratio, SD = Standard Deviation, CI=confidence interval, OR=odds ratio, and TRAIL 
= TNF-related apoptosis-inducing ligand.  
3.3.6 Anti-inflammatory cytokines 
None of the investigated anti-inflammatory cytokines, including IL-1ra, IL-4, IL-5, and IL-13, 
were detectable.  
3.3.7 Growth factors 
3.3.7.1 PDGF-AB/BB 
Patients who were male (p=0.02), younger (p=0.0005), and had smoking status (p=0.048) were 
more likely to have higher levels of PDGF-AB/BB. PDGF-AB/BB levels also significantly 
correlated with delay to blood draw (p=0.03). Only age was independently associated with 
PDGF-AB/BB levels (p=0.002). 
Patients who had a recurrent vascular event (40.0 ng/mL) had a lower level of PDGF-AB/BB, 
compared with those who remained free of recurrent vascular events (51.0 ng/mL) (p=0.004) 





Table 12. In univariate analysis, higher levels of PDGF-AB/BB were significantly associated with 
a lower risk of recurrent vascular events. After adjusting for potential confounders in multivariate 
analysis, higher levels of PDGF-AB/BB were independently associated with a lower risk of 
recurrent vascular events (HR per SD increase of square-root transformed PDGF-AB/BB levels, 
0.60; 95% CI, 0.42-0.85). PDGF-AB/BB was not predictive of death or dependency. 
Levels of PDGF-AB/BB were not different in patients with and without cognitive deterioration. 
Results of Cox regression and logistic regressions predicting cognitive outcomes are summarized 
in Table 13. PDGF-AB/BB was not predictive of any cognitive outcome investigated (p>0.05).   
3.3.7.2 VEGF 
Patients who were older (p=0.01) and had hypertension (p=0.02) were more likely to have higher 
levels of VEGF. 
Levels of VEGF were slightly lower in patients who experienced a recurrent vascular event (340 
pg/mL), compared with those did not (346 pg/mL), with a marginal statistical significance 
(p=0.05). VEGF was not predictive of any vascular outcome investigated in regression analyses 
(Table 12).  
Patients who were determined to have a significant cognitive decline (172 pg/mL) had lower 
levels of VEGF, compared with those who did not (256 pg/mL) (Figure 12). In univariate 
analysis, higher VEGF was significantly associated with lower risk of significant cognitive 
decline. After adjusting for potential confounders in multivariate analysis, a higher VEGF was 
independently associated with lower risk of significant cognitive decline (OR per SD increase of 
square-root transformed VEGF levels, 0.45; 95% CI, 0.26-0.77) (Table 13). VEGF was not 
predictive of incident dementia. Delay to blood draw did not have any significant effect 






GM-CSF levels significantly correlated with delay to blood draw (p=0.01). There was a weak 
correlation between VEGF and GM-CSF levels with marginal statistical significance (Spearman’s 
ρ=0.11; p=0.06). 
Levels of GM-CSF were not different in patients with and without an outcome event. Levels of 
GM-CSF were not predictive for any outcome investigated (Table 10-11). 
3.3.7.4 LIF and M-CSF 
LIF and M-CSF were below detection range.  
Figure 11. Box plots of distributions of PDGF-AB/BB levels in patients with or without a 
recurrent vascular event 
 
PDGF-AB/BB = platelet-derived growth factor-AB/BB 
Table 12. Cox regression analysis of the association of growth factor levels with death, 
recurrent vascular events, and dependency 
 HR per SD increase of growth factor levels (95% CI) 
Death Recurrent vascular events  
(composite endpoint of recurrent 





Univariate  0.94 (0.60-1.50) 0.61 (0.44-0.84) 0.70 (0.48-1.02) 
Multivariate    





     Model 1  0.62 (0.46-0.85)  




Univariate  0.86 (0.50-1.46) 0.72 (0.51-1.02) 0.79 (0.53-1.19) 
GM-CSF
*
    
Univariate     
     < 0.2 pg/mL (ref) 1.00 1.00 1.00 
     ≥ 0.2 pg/mL 0.90 (0.34-2.39) 0.76 (0.39-1.49) 0.45 (0.20-1.01) 
 
* 
Due to depletion of serum samples, the sample size was 287 for VEGF and GM-CSF, and 309 
for PDGF-AB/BB. 
Recurrent vascular events: model 1 adjusted for treatment; model 2 adjusted for treatment, age, 
gender, baseline MMSE score, previous vascular events, diabetes mellitus, hypertension, stroke 
subtype, hyperlipidemia, and smoking.  
HR=hazard ratio, SD=standard deviation, IS=ischemic stroke, MI=myocardial infarction, 
ICH=intracerebral hemorrhage, PDGF-AB/BB = Platelet Derived Growth Factor-AB/BB, VEGF 
= Vascular Endothelial Growth Factor, and GM-CSF=granulocyte-macrophage colony 
stimulating factor. 
Table 13. Cox and logistic regression analysis of the association of growth factor levels with 
incident dementia and significant cognitive decline 
 HR per SD increase of 
growth factor levels (95% CI) 
OR per SD increase of growth 
factor levels (95% CI) 








Univariate  0.95 (0.52-1.76) 0.64 (0.43-0.97) 
Multivariate    
     Model 1  0.50 (0.31-0.82) 
     Model 2  0.45 (0.26-0.77) 
GM-CSF
*
   
Univariate    
     < 0.2 pg/mL (ref) 1.00 1.00 
     ≥ 0.2 pg/mL 0.54 (0.16-1.83) 0.95 (0.44-2.03) 
*
Due to depletion of serum samples, the sample size was 244 for VEGF and GM-CSF, and 266 
for PDGF-AB/BB. 
Significant cognitive decline: model 1 adjusted for baseline MMSE score, age, and previous 
vascular events; model 2 adjusted for baseline MMSE score, age, previous vascular events, 





HR=hazard ratio, SD = Standard Deviation, CI=confidence interval, OR=odds ratio, PDGF-
AB/BB = Platelet Derived Growth Factor-AB/BB, VEGF = Vascular Endothelial Growth Factor, 
and GM-CSF=granulocyte-macrophage colony stimulating factor. 
Figure 12. Box plots of distributions of VEGF levels in patients with or without significant 
cognitive decline 
 
VEGF = vascular endothelial growth factor. 
3.3.8 Other baseline characteristics 
Results of Cox regression analyses predicting vascular outcomes are summarized in Table 14. 
Diabetes was the only independent predictor for death; treatment was the only independent 
predictor for recurrent vascular events; gender was the only independent predictor for dependency.  
Results of Cox and logistic regression analyses predicting cognitive outcomes are summarized in 
Table 15. Previous vascular events and baseline MMSE score were independent predictors for 
incident dementia; age, previous vascular events, and baseline MMSE score were independent 
predictors for significant cognitive decline. 
  





Table 14. Cox regression analyses of the association of other baseline characteristics with death, recurrent vascular events, and 
dependency 
 HR (95% CI) 
 Death Recurrent Vascular Events Dependency (1 missing) 
 Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Gender        
     Male
 
(ref) 1.00  1.00  1.00 1.00 
     Female 2.27 (0.90−5.76)  0.99 (0.50−1.97)  4.87 (2.04-11.7) 3.55 (1.35-9.38) 
Ethnicity       
     Chinese
 
(ref) 1.00  1.00  1.00  
     Malay 0.72 (0.10-5.44)  0.36 (0.05-2.67)  1.20 (0.28-5.12)  
     Indian 0.58 (0.08-4.34)  0.92 (0.28-3.01)  1.41 (0.42-4.77)  
Age 1.05 (1.01−1.10) 1.05 (0.99-1.10) 1.01 (0.98−1.04)  1.03 (1.00-1.07)  
Education        
     Nil/Primary
 
(ref) 1.00  1.00  1.00 1.00 
     Secondary/Tertiary 0.98 (0.38−2.52)  0.96 (0.48−1.90)  0.28 (0.10-0.82) 0.40 (0.11-1.47) 
Previous Vascular Events 1.70 (0.66-4.38)  1.42 (0.71-2.85)  0.83 (0.33-2.09)  
Hypertension  6.32 (0.84-47.5)  1.45 (0.63-3.33)  1.17 (0.47-2.93)  
Hyperlipidemia 0.80 (0.31-2.07)  0.57 (0.28-1.16)  0.61 (0.26-1.41)  
Smoking  1.98 (0.79-5.00)  0.62 (0.29-1.32)  0.69 (0.29-1.66)  
Diabetes Mellitus 5.32 (1.89−15.0) 4.91 (1.72-14.0) 1.55 (0.79−3.03)  2.83 (1.28-6.24) 1.56 (0.63-3.85) 
Stroke Subtype       
     TIA
 
(ref) 1.00  1.00  1.00 1.00 
     POCI/LACI 3.94 (0.52-30.0)  2.05 (0.72−5.86)  2.70 (0.63-11.6) 0.99 (0.21-4.68) 
     TACI/PACI 6.75 (0.70−64.9)  1.51 (0.34−6.75)  5.24 (1.02-27.0) 3.13 (0.54-18.0) 
Baseline MMSE Score 0.90 (0.82-0.98)  0.93 (0.87-1.00)  0.84 (0.79-0.90) 0.95 (0.85-1.06) 
Baseline mRS Score 1.62 (0.97-2.71)  1.22 (0.84-1.79)  1.95 (1.25-3.03) 1.66 (0.98-2.81) 





     Aspirin (ref) 1.00  1.00  1.00  
     Aspirin + Dipyridamole 0.76 (0.29-1.95)  0.34 (0.15-0.80)  0.62 (0.26-1.46)  
     Anticoagulant −*  1.43 (0.54-3.81)  0.74 (0.17-3.30)  
*
 No patient allocated to treatment by anticoagulant died during the course of study; hence regression analyses for these patients could not be 
performed.  
HR=hazard ratio, CI=confidence interval, TIA=transient ischemic attack, POCI=posterior circulation infarct, LACI=lacunar infarct, TACI=total 
anterior circulation infarct, PACI=partial anterior circulation infarct, MMSE=mini-mental state examination, and mRS=modified Rankin scale. 
 
Table 15. Cox and logistic regression analysis of the association of other baseline characteristics with incident dementia and logistic 
regression analysis predicting significant cognitive decline  
 HR (95% CI)  OR (95% CI) 
Incident Dementia  Significant Cognitive Decline 
Univariate Multivariate  Univariate Multivariate 
Gender       
     Male
 
(ref) 1.00   1.00  
     Female 1.00 (0.30-3.33)   2.00 (0.97-4.14)  
Ethnicity       
     Chinese
 
(ref) 1.00   1.00  
     Malay
*
 ―   0.42 (0.05-3.32)  
     Indian  1.83 (0.40-8.36)   1.29 (0.41-4.04)  
Age 1.13 (1.06−1.22) 1.06 (0.98-1.13)  1.08 (1.04−1.13) 1.05 (1.00-1.09) 
Education       
     Nil/Primary
 
(ref) 1.00   1.00 1.00 
     Secondary/Tertiary 0.30 (0.06−1.35)   0.36 (0.15−0.86) 1.03 (0.38-2.82) 
Previous Vascular Events 4.06 (1.29−12.8) 3.46 (1.03-11.6)  2.51 (1.19−5.32) 2.36 (1.01-5.48) 
Hypertension 4.24 (0.55−32.9)   3.07 (1.04−9.05) 1.67 (0.51-5.39) 
Hyperlipidemia  1.63 (0.52-5.14)   1.48 (0.72-3.05)  






 No patient of Malay ethnicity converted to dementia during the course of study; hence regression analyses for these patients could not be 
performed. 
HR=hazard ratio, CI=confidence interval, OR=odds ratio, TIA=transient ischemic attack, POCI=posterior circulation infarct, LACI=lacunar 
infarct, TACI=total anterior circulation infarct, PACI=partial anterior circulation infarct, MMSE=mini-mental state examination, and 
mRS=modified Rankin scale. 
Diabetes Mellitus 0.93 (0.28-3.10)   1.46 (0.71-3.03)  
Stroke Subtype      
     TIA
 
(ref) 1.00   1.00  
     POCI/LACI 2.61 (0.33-20.6)   1.85 (0.62-5.57)  
     TACI/PACI 4.32 (0.39-47.7)   2.14 (0.49-9.34)  
Baseline MMSE Score 0.74 (0.67-0.82) 0.79 (0.70-0.89)  0.81 (0.74-0.88) 0.85 (0.77-0.95) 
Baseline mRS Score 2.07 (1.17-3.66) 1.70 (0.95-3.06)  1.80 (1.21-2.66) 1.33 (0.84-2.10) 
Treatment       
     Aspirin (ref) 1.00   1.00  
     Aspirin + Dipyridamole 1.01 (0.31-3.32)   1.07 (0.51-2.25)  






4.1 Evaluation and implication of results 
4.1.1 sVCAM-1 and sICAM-1 
Previous studies by Castillo et al found that baseline sVCAM-1 levels were independently 
associated with recurrent vascular events in patients recruited within 1-3 months of ischemic 
onset
56
. Consistent with previous findings, we demonstrated that serum sVCAM-1 levels 
independently predicted recurrent vascular events in our cohort of non-disabled stroke patients. In 
addition, in the present thesis, we found that sVCAM-1 levels independently predicted death from 
all causes. Therefore, sVCAM-1 may serve as a potential prognostic biomarker in ischemic stroke. 
There is growing evidence that inflammation is implicated in vascular diseases. However, the 
mechanisms underlying the association between sVCAM-1 and unfavorable prognosis has not 
been established. One possible explanation is that increased levels of sVCAM-1 reflect increased 
expression of VCAM-1 on cerebral endothelial cells. As an important adhesion molecule, 
VCAM-1 has been demonstrated to facilitate the infiltration of peripheral leukocytes including 
monocytes and neutrophils into the ischemic area, which may subsequently worsen ischemic 
brain injury by secreting various cytokines and inflammatory factors
42
. Another possibility is that 
increased sVCAM-1 levels may reflect higher concentrations of other cytokines which upregulate 
VCAM-1 expression in the brain, such as TNF-α and IL-1β42, which have been shown to cause 
inflammatory brain damage. Hence, it is of interest for future studies to investigate the roles of 
these important inflammatory markers. Notably, these detrimental effects may not be limited 
locally to the brain, but may promote a systemic inflammatory response. Further studies are 
needed to elucidate whether the association between sVCAM-1 and adverse outcomes is an 
epiphenomenon or a causal relationship. If a causal relationship can be determined, inhibition of 
VCAM-1 with anti-VCAM-1 antibodies at the convalescent stage may serve as a potential 





Previous studies have demonstrated that levels of sVCAM-1 and sICAM-1 are elevated in AD 
and correlate with MMSE score in the aging population
255, 256
. Similarly, in the present thesis, we 
found a negative correlation between sVCAM-1 levels and baseline MMSE score in stroke 
patients, which cannot be fully explained by confounding effects of covariates including gender, 
age, race, education, diabetes mellitus, stroke subtype, hypertension, and baseline mRS score.  
Nevertheless, there was no association of blood marker levels with the risk of incident dementia 
and significant cognitive decline at follow-up. Our results showed that sVCAM-1 levels were 
associated with baseline cognitive performance, but did not predict future cognitive decline and 
dementia. Accordingly, determination of serum levels of sVCAM-1 may provide additional 
information on the cognitive functions of stroke survivors, which may be used in complement to 
the cognitive tests in order to achieve more accurate and reliable diagnosis for post-stroke 
cognitive impairment and dementia.     
In the present thesis, we did not find an association between levels of sICAM-1 and stroke 
outcome. Nonetheless, several studies in acute stroke patients (< 24 hours) showed that levels of 





findings suggest that sICAM-1 may play more important roles at the acute stage after ischemic 
onset, whereas sVCAM-1 is more important at the convalescent stage. A possible reason for the 
temporal differences observed is that sICAM-1 levels rise acutely and transiently after stroke; in 




The present thesis demonstrated that a higher level of PDGF-AB/BB was independently 
associated with a lower risk of recurrent vascular events in a cohort of non-disabled stroke 
patients. The Loss of stability of a carotid artery atherosclerotic lesion and transformation into an 
unstable morphology is one of the important causes of ischemic stroke, since the unstable lesion 





formation of new microvessels within the vessel wall, is an important process in the pathology of 
atherogenesis. Apart from endothelial cell invasion and proliferation, the coverage of vascular 
sprouts by mural cells such as vascular smooth muscle cells and pericytes is also important for 
angiogenesis by structurally stabilizing the newly formed vessels
259
. PDGF, which not only have 
direct angiogenic effects on endothelial cell migration and proliferation
260
, but also mediates the 
interaction of endothelial cells and pericytes
156
 and promotes the recruitment of vascular smooth 
muscle cells
261
, thereby maintaining the homoeostatsis and promoting the maturation of blood 
vessels
162
, is therefore essential for the angiogenic processes. It has been previously demonstrated 
that following PDGF receptor blockade, angiogenesis is reduced in the absence of PDGF
262
, 
which supports the hypothesis that PDGF promotes the release of pro-angiogenic agents and 
mural cell recruitment
263
. In a previous study by Chowdhury et al
169
, levels of PDGF were found 
to be lower in patients with symptomatic carotid disease at risk of plaque instability compared 
with those who were asymptomatic. Therefore, a possible explanation for the observed 
association between a higher level of PDGF-AB/BB and a lower risk of recurrent vascular events 
is that lower levels of PDGF may result in less stable blood vessels due to impaired or reduced 
recruitment of mural cells, hence a greater risk of plague instability and accordingly recurrent 
vascular events
169
. The present finding suggests that PDGF-AB/BB may serve as a prognostic 
marker for recurrent vascular events and a potential non-acute therapeutic target in 
complementary with conventional treatment in stroke patients. However, more studies need to be 
conducted to fully elucidate the underlying mechanism of the observed association. 
In the present thesis, we failed to find an association between PDGF-AB/BB levels and the risk of 
death (from all causes), dependency, incident dementia, or significant cognitive decline. It is 
conceivable that PDGF-AB/BB, which plays more important roles in vascular pathophysiology, 
is not associated with death from all causes which includes death from cancer and pulmonary 





functional outcome after stroke. One possible explanation is that since functional recovery is a 
central nervous system-dependent process, it is the local levels of PDGF-AB/BB in the brain that 
better reflect the extent of recovery, as opposed to peripheral levels of PDGF-AB/BB, which may 
not truthfully represent the brain levels. Therefore, PDGF-AB/BB levels in the cerebral spinal 
fluid may probably provide more accurate predictions.  
4.1.3 VEGF 
The present thesis demonstrated that a higher level of VEGF was independently associated with a 
lower risk of significant cognitive decline in a cohort of non-disabled stroke patients. VEGF 
mainly functions as a vascular permeability factor at the acute phase after cerebral ischemia, 
whereas its angiogenic effects predominate at the recovery phase
172
. Moreover, VEGF possesses 
neurotrophic, neuroprotective, and neuroproliferative properties
153
. VEGF has also been found to 
have beneficial effects on cognition, particularly memory. Intra-hippocampal administration of 
VEGF receptor blocker impairs long-term memory
264
. Kangen-karyu ameliorated aging-related 
memory deﬁcit at least partly through reversing the expression of VEGF mRNA and protein in 
the brain
265
. Furthermore, intracerebroventricular administration of VEGF to rats undergone 
MCAO improved cognitive functions as shown by better performance in Morris water maze
224
. 
The underlying mechanism of such beneficial effects of VEGF on cognition remains to be fully 
elucidated. Previous studies have reported that VEGF increases plasticity of mature neurons
266
, 
increases the number of neuronal precursor cells and prevents loss of endothelial cells
267
, and 
leads to a 2 fold increase in neurogenesis in the hippocampus, which were associated with 
improved cognitive performance
268
. Therefore, it may be speculated that the lower risk of 
significant cognitive decline observed in patients with higher levels of VEGF is attributed to 
VEGF-induced neurogenesis and increase of plasticity of existing neurons. Although we did not 
observe a reduced risk of incident dementia in stroke patients with higher VEGF levels, possibly 





positive roles of VEGF in preventing post-stroke cognitive deterioration. Lower VEGF levels 
may therefore serve as a prognostic marker to identify patients at high risk of cognitive 
deterioration who may subsequently be targets for therapeutic intervention. If other studies 
confirm the association between VEGF and post-stroke cognitive decline, VEGF may potentially 
be of use in preventing post-stroke cognitive decline in high risk patients.  
We failed to observe an association between VEGF and the risk of death (from all causes), 
recurrent vascular events, and dependency in this thesis. While it is conceivable that VEGF, an 
angiogenic and neuroprotective factor, is not predictive of death from all causes and recurrent 
vascular events, VEGF has led to interest in its applicability in ameliorating neurological deficits 
after stroke. Continuous intravenous administration of VEGF after MCAO also improves motor 
and proprioceptive functions in rats
269
. Transplantation of VEGF transfected neuronal stem cells 
into the striatum of rats after MCAO led to improved long-term motor, sensory, reflex, and 
balance functions
270
. Furthermore, reduced infarct size and better neurological function could be 
observed as early as 3 days post-stroke in VEGF-treated rats
269
, as opposed to improved cognitive 
functions which could not be seen until at a delayed stage (25 days post-stroke)
224
. Nonetheless, 
as described previously, the patients of the present thesis had similar extent of neurological 
deficits as measured by the mRS
253
 when they entered the study, the majority at the convalescent 
stage (median, 47 days post-stroke). It is conceivable that by that time, the positive effects of 
VEGF on neurological functions had largely been established; hence, the inter-patient variation in 
VEGF levels at that stage may not have much influence on future recovery of neurological 
functions.   
4.1.4 CRP 
Although previous studies in unselected patients showed that elevated CRP levels are associated 
with unfavorable outcomes after stroke
113-116, 271
, the present thesis demonstrates that in a group of 





dependency. Studies have indicated that CRP levels are strongly associated with stroke severity 
due to an acute inflammatory response proportional to the extent of initial cerebral damage
272
. 
Hence, in studies including a wide range of stroke severity, the observed association between 
CRP and unfavorable outcomes may be confounded by stroke severity. Although previous studies 
adjusted for stroke severity in multivariate analyses, confounding effects by stroke severity were 
minimized in the present thesis by including only patients with non-disabled strokes, which is one 
strength of the present thesis. Yet another strength of the current thesis is that we included only 
patients with blood drawn at the convalescent stage. CRP levels at this stage better reflect the 
basal state of inflammation rather than stroke induced acute inflammation, which is influenced by 
stroke severity. As such, in this thesis we are able to study the association of CRP with 
unfavorable outcomes with minimized confounding due to both acuteness of CRP measurement 
and stroke severity. Nonetheless, due to the inclusion criteria of the ESPRIT study for less severe 
stroke survivors with mRS ≤ 3, the incidence of outcome events was relatively low compared 
with other stroke studies. Idicula et al
272
 reported a HR of approximately 2.3 per tertile increase of 
CRP for predicting death. Given a SD of 0.82 and an event probability of 6% of the present thesis, 
the estimated power to detect such an association between CRP and death is 78%. Purroy et al
273
 
reported a HR of 2.71 for patients with CRP level > 4.1 mg/L compared with those with CRP 
level ≤ 4.1 mg/L for predicting recurrent vascular events. Given a SD of 0.5 and an event 
probability of 9% in the present thesis, the estimated power to detect such an association is 66%. 
Therefore, although it seems unlikely, we cannot rule out the possibility that it was due to the low 
event rate, thus relatively low statistical power of this thesis that we failed to detect an association.            
Additionally, results of this thesis revealed a trend of ethnic differences in CRP levels, which was 
of marginal statistical significance. Specifically, patients of Indian ethnicity were more likely to 
have higher levels of CRP than those of Chinese or Malay ethnicities. Likewise, previous studies 





Chinese and Japanese women
274
. A number of contributing factors may account for this variation 
including body-mass index and polymorphisms in the CRP gene
274, 275
. Furthermore, it has been 
shown in a number of inter-ethnic studies conducted in Singapore that patients of Indian ethnicity 
have a higher prevalence of peripheral vascular disease, ischemic heart disease, and stroke
276-278
. 
While further research is required to fully account for the impact of ethnic differences on CRP 
levels, this finding implies that the ethnicity of the patient needs to be considered if CRP levels 
were to be interpreted for prognosis after stroke.   
4.1.5 Other markers 
Levels of MCP-1 (p=0.02) and IL-16 (p=0.04) were significantly higher in patients who died 
compared with those who survived. Levels of MIF (p=0.03) were significantly higher in patients 
who had a recurrent vascular events compared with those who did not. Levels of IL-16 (p=0.03) 
were significantly higher in patients who became dependent compared with those who did not. 
Levels of MIG (p=0.01) were significantly higher in patients who were determined to have a 
significant cognitive decline. Nevertheless, these markers were not significantly associated with 
outcomes in regression analyses in the current thesis. In spite of this, our results may not be 
conclusive enough to dismiss these molecules as possible prognostic markers for ischemic stroke. 
Although whether serum levels of these markers may not be useful to predict outcomes for 
individual patients remains to be ascertained, the presence of elevated levels of these markers in 
patients who experienced an outcome event suggests possible involvement of these molecules in 
propagating the initial injury caused by cerebral ischemia, which may be indirect.  
Additionally, apart from sVCAM-1, levels of MIG (p<0.0001) and IL-16 (p=0.001) also had 
significant negative correlations with baseline MMSE scores. Nevertheless, after adjusting for 
potential confounding covariates, neither MIG nor IL-16 was independently associated with 
baseline MMSE score, which suggests that the observed correlation of these molecules with 





4.2 Clinical significance of results 
4.2.1 Prognosis 
As shown in the present thesis, a higher level of sVCAM-1 was independently associated with a 
higher risk of death and recurrent vascular events, while a higher level of PDGF-AB/BB was 
independently associated with a lower risk of recurrent vascular events in a cohort of non-
disabled stroke patients who were at the convalescent stage. Therefore, these two markers may be 
useful in ischemic stroke as part of a clinically useful prognostic model, which is of great 
importance to patient management. However, to be clinically useful, markers need to add 
predictive power to validated clinical model (for instance the SSV model) and be validated in a 
separate cohort of patients. A potential problem with the applicability of blood marker in 
predicting stroke outcomes is that the basal levels of inflammatory markers may exhibit 
considerable inter-patient variations, probably due to various genetic and environmental causes. 
Consequently, the application of a single cut-off value for outcome prediction may be misleading. 
Ideally, basal levels of inflammatory markers of the patient, or at least levels estimated from 
factors known to modulate basal inflammatory marker levels, should be cautiously taken into 
account when interpreting information conveyed by inflammatory markers in outcome prediction 
for individual patients after stroke. As the use of biomarkers for prognosis is still under research, 
further studies certainly need to be conducted to validate and generalize their applicability.   
4.2.2 Treatment and secondary prevention 
In addition to providing prognostic information, these markers may also suggest possible 
mechanisms for unfavorable outcomes and therefore serve as therapeutic targets for stroke 
treatment and secondary prevention. Among the potential therapeutic approaches targeting the 
ischemic cascade, experimental studies suggest that the suppression of inflammatory responses 
may offer beneficial effects after ischemic stroke. Immunotherapy after cerebral ischemia also has 





narrow therapeutic window of 4.5 hours, since immunological responses may sustain for days to 
months after ischemic onset, immunotherapy may have an extended therapeutic window. Rodent 
experiments have shown that immunosuppressing treatments were efficacious when administered 
12-24 hours after ischemic onset
279, 280
. Therefore, immunotherapy may be administered to 
patients who missed the therapeutic window of thrombolysis, or even patients at the convalescent 
stage. In addition, since inflammation has been implicated in reperfusion injury
36
, 
immunosuppression may be administered as a complementary treatment for thrombolytics.  
Possible pharmacological treatments could be based on the inhibition of pro-inflammatory 
mediators, such as adhesion molecules. Anti-ICAM-1 antibodies have been investigated in 
various clinical trials, but they were not found to be efficacious. A number of reasons have been 
proposed to explain the lack of efficacy. First of all, since the antibodies administered to the 
patients were of mouse origins, considering the increased frequency of fever among treated 
patients, anti-foreign inflammatory responses might have been activated, which was reproduced 
by administering mouse antibodies to rats
281
. Secondly, anti-ICAM-1 antibodies have been 
reported to be particularly effective in reperfusion injury
282
, and may therefore only be efficacious 
in combination with thrombolysis
283
; however, most patients recruited for the trial had focal 
permanent ischemia. Thirdly, the timing and route of administration may be important factors 
affecting the efficacy of anti-ICAM-1 treatments. Seldom were anti-ICAM-1 antibodies 
administered beyond 1 hour after reperfusion, whereas in the trials, anti-ICAM-1 antibodies were 
often administered at a much delayed time. Besides, systemic administration of anti-ICAM-1 
antibodies might have compromised the immunological defense of the patients, which may result 
in a higher possibility of infections. Finally, since inflammatory responses are often modulated by 
redundant pathways. Hence, the desired effect may not be achieved by blocking a single signaling 
cascade. In this context, blocking mediators which are more upstream of the inflammatory 





Results of the present thesis indicate that VCAM-1 may be a promising therapeutic target for 
prevention of recurrent vascular events for stroke survivors at the convalescent stage. However, it 
has been previously reported by Justicia et al
284
 that blockade of VCAM-1 by anti-VCAM-1 
antibodies did not decrease leukocyte infiltration into rat brains or protect against ischemic 
damage in either rats or mice. Nevertheless, their results are inconclusive for simply dismissing 
anti-VCAM-1 antibodies as an ineffective treatment in ischemic stroke, since some of the 
problems in the translation from bench to bedside for anti-VCAM-1 antibodies were also present 
in their study design. Firstly, the rats received anti-VCAM-1 antibodies 30 minutes after 
reperfusion while the mice 90 minutes after reperfusion and 3 more times thereafter every 24 
hours. Results of previous clinical studies and the present thesis indicate that, in contrast to 
ICAM-1, VCAM-1 is associated with stroke outcomes at the convalescent stage, but not at the 
acute stage. Hence, it is conceivable that blockade of VCAM-1 at the acute stage in rats may not 
decrease leukocyte infiltration or exert beneficial effects. Secondly, antibodies of mouse origin 
were injected to rats and antibodies of rat origin were injected to mice. It has been shown that 
antibodies generated in a different species may play immunogenic roles in the host, thereby 
diminishing the potential beneficial effects of treatment. Thirdly, anti-VCAM-1 antibodies were 
administered systemically for both mice and rats, which may be counterproductive due to the 
compromised immune defense of the host. Fourthly, neurological score and infarct volume were 
examined as study endpoints. Nevertheless, as indicated in the present thesis, higher VCAM-1 is 
associated with higher risk of death and recurrent vascular events, but VCAM-1 may not be 
involved in infarct growth or determining functional outcomes. Hence, other study endpoints such 
as death need to be investigated before a conclusion may be made. Finally, the study endpoints 
were examined at day 2 for rats and at day 4 for mice only. It would be more appropriate to 
extend the time points, as protective effects of blockade of VCAM-1 may not be obvious until in 





fully elucidate the roles of VCAM-1 in cerebral ischemia and comprehensively evaluate the 
effects of VCAM-1 inhibition.  
Another possible pharmacological treatment could be based on enhancing the effects of growth 
factors such as PDGF-AB/BB. Since results of this thesis suggest that PDGF-AB/BB may be 
protective against recurrent vascular events through stabilizing plagues in the blood vessels at the 
convalescent stage, a possible way of therapeutic intervention is to locally inject PDGF-AB/BB 
near the identified plagues. Thus far, no experimental study has investigated the effects of 
administering PDGF-AB/BB after cerebral ischemia. In view of the complex responses of the 
body to ischemic stroke and the problems encountered in previous studies on VCAM-1 and 
ICAM-1, various parameters, including timing, route of administration, interaction of different 
pathways, and long term effects of therapeutic interventions need to be taken into consideration 
during experimental design. Although animal models cannot fully represent the conditions in 
human disease, they may convey important information if the experiments are adequately 
designed and the results interpreted and translated with caution.    
Post-stroke cognitive outcome, on the other hand, may be improved by enhancing the effects of 
growth factors such as VEGF. However, great caution needs to be paid when targeting VEGF as a 
therapeutic intervention, owing to its biphasic roles during cerebral ischemia. Early intravenous 
administration of VEGF may worsen post-ischemic brain edema or hemorrhage
176, 285
 and clinical 
outcomes. In contrast, delayed administration of VEGF has shown benefit. For instance, VEGF 
intravenously injected 1 hour after ischemic onset increased BBB leakage, hemorrhagic 
transformation and infarct volume; however, when treatment was delayed until 48 hours post-
stroke, intravenously administered VEGF enhanced angiogenesis and functional recovery
176
. As 
suggested by findings of the present thesis, in order to improve cognitive outcomes after cerebral 
ischemia, VEGF should be administered at the convalescent stage, so that the potential risk of 





important, since only intracerebralventricular injection of VEGF has been demonstrated to protect 
the brain against ischemic injury
286
.   
Although post-ischemic immunosuppression is a promising target for stroke treatment and 
secondary prevention, just as every coin has two sides, there are also some problems associated 
with anti-inflammatory interventions. Immune cells and inflammation not only exert detrimental 
effects on the ischemic brain at the acute stage, but also play a key part in tissue reorganization 
and recovery at the convalescent stage. Pro-survival effects of immune cells include growth factor 
production, angiogenesis, neurogenesis, and neuroplasticity
287
. Moreover, pro-inflammatory 
response is also required for vascular remodeling and would healing
31
. Macrophage depletion has 
been demonstrated to inhibit vascular remodeling and production of pro-inflammatory cytokines 
and chemokines were essential for improved recovery
288
. In addition, as mentioned previously, 
immunosuppression increases the chance of infections, which is a major determinant of 
neurological outcome, dependency, and death
289
, possibly through increasing the expression of 
co-stimulatory molecules as well as promoting antigen presentation and autoimmunity
130, 290
. 
Therefore, inhibiting the general pro-inflammatory responses may be counterproductive as a 
treatment of ischemic stroke. A more in-depth and comprehensive understanding of both the 
acute and delayed pathophysiology of ischemic stroke is certainly necessary to develop a 
treatment which selectively suppress the deleterious inflammatory responses without hindering 
the beneficial responses.      
4.3 Strengths and limitations 
This thesis had several methodological strengths. Firstly, the prospective design allows for 
determination of the temporal relationship between the exposures and outcomes. Secondly, both 
vascular and cognitive outcomes were assessed in the present thesis. Thirdly, potential 
confounding effects of established predictors for stroke outcomes such as age and stroke severity 





As such, whether the inflammatory markers add additional information to established predictors 
could be evaluated. Especially, studies have showed that levels of some inflammatory markers 
such as CRP, sVCAM-1 and sICAM-1 are associated with stroke severity
3
, most likely due to an 
inflammatory response proportional to the degree of initial cerebral damage. Since stroke severity 
itself is a strong predictor for outcome, by using a selected group of non-disabled stroke patients, 
we may exclude such a confounding effect. Fourthly, the majority (83%) of our serum samples 
were collected at the convalescent stage (>7 days post stroke onset), which may better reflect a 
trait of the extent of basal inflammation in patients rather than merely a state of acute 
inflammation, which is especially important when long-term outcomes are studied. Finally, when 
there is an association between an inflammatory marker and stroke outcomes, the association is 
generally continuous, as opposed to dichotomous. Moreover, when a continuous variable is 
categorized, at least part of the information conveyed by the variable may be lost. However, in 
many previous studies, thresholds were calculated with the aid of ROC curve analysis, in order to 
optimize the prognostic performance of inflammatory markers, which may result in artificially 
over-estimated effect sizes. When such data-derived thresholds are repeated in a separate cohort, 
the same results often could not be observed
291
 . In the present thesis, inflammatory markers were 
analyzed continuously, except when continuous analysis was not possible (for instance due to 
undetectable levels in a large proportion of patients); therefore, the effect sizes reported in this 
thesis are more accurate and reliable.  
On the other hand, there are several limitations to this thesis. First of all, since the ESPRIT study 
restricted patient inclusion to those with TIAs and minor strokes, which resulted in a younger and 
healthier cohort than many other stroke cohorts, it is conceivable that the incident rates of 
unfavorable outcome events, thus statistical power, were relatively low in this thesis. We cannot, 
therefore, exclude the possibility that the moderate statistical power have led to some false-





patients recruited. Patients included in analysis and those not included were similar in baseline 
characteristics, except for that patients not included in analysis were more likely to have diabetes 
mellitus and previous vascular events, but less likely to have hyperlipidemia. It is conceivable 
that patients with diabetes mellitus and previous vascular events may have higher levels of 
inflammatory markers and worse outcomes; their exclusion from analysis could have biased us 
toward no association between inflammatory markers and stroke outcome. As there is no 
evidence of effect modification by hyperlipidemia on the association between inflammatory 
markers and stroke outcome, this difference is unlikely to affect our results. Thirdly, owing to the 
fact that the majority of our patients were at the convalescent stage after stroke, conceivably, 
levels of the inflammatory markers may have subsided to their basal levels, as opposed to the 
exceptionally high levels measured at the hyperacute or acute stages. Unfortunately, levels of 
markers which remain at very low levels in the circulation except under acute inflammatory 
conditions, especially certain pro-inflammatory cytokines and anti-inflammatory cytokines, were 
below the detection limits of our experimental technique. They may, however, potentially convey 
important prognostic information which we have missed out. Thirdly, we do not have any data on 
whether there was any active sub-clinical infection present when serum samples were collected. 
In this context, serial measurements of the blood markers would be more appropriate but 
logistically difficult. Nevertheless, our patients had less severe strokes and were at the 
convalescent stage, thus less likely to suffer from infections or secondary complications than 
acute patients. We therefore believe that the blood marker levels measured reflect a trait of 
inflammatory response. Fourthly, since serum samples were obtained at a median of 47 days after 
the index event, information on early recurrences was not available. Next, data on etiology was 
not collected, hence precluding analysis by etiological subtypes, which may be important for 
evaluating the prognostic value of markers such as CRP. Finally, due to the inclusion criteria of 
the ESPRIT study for non-disabled stroke survivors, the findings of this thesis may be difficult to 





4.4 Future studies 
First of all, there is a need to conduct a validation study in another prospective cohort. If the same 
results could be observed in a different cohort of patients, the reproducibility and reliability of the 
results would be ascertained.   
Secondly, as previously mentioned, ten out of the 24 selected analytes were below the detection 
range of our experimental technique. Therefore, it would be of interest to determine levels of 
these ten analytes using other more sensitive quantitative techniques such as ELISA.  
Thirdly, genetic polymorphisms of the inflammatory markers may be investigated. It has been 
shown that certain genetic polymorphisms are associated with elevated basal levels of some 
inflammatory markers, including CRP and IL-6. In light of this fact, additional cautions need to 
be employed when interpreting these inflammatory markers for the purpose of prognosis.   
Finally, another possible future study is to establish the mechanism underlying the observed 
associations of sVCAM-1 and PDGF-AB/BB with outcomes, and to evaluate their potential 
therapeutic effects in rodent models of focal ischemic stroke. For example, anti-VCAM-1 
antibodies may be administered to rodents undergone transient middle cerebral artery occlusion 
(MCAO). A previous study reported that anti-VCAM-1 antibodies did not reduce the extent of 
ischemic damage in rats or mice. However, anti-VCAM-1 antibodies were injected at the acute 
stage after stroke (30 minutes after reperfusion in rats and from 90 minutes to 3 days after 
reperfusion in mice). Results of previous and our studies suggest that VCAM-1 may have more 
important roles to play at the convalescent stage after stroke, rather than at the acute stage. 
Therefore, results may be more promising if inhibition of VCAM-1 was initiated at a more 
delayed stage in future rodent ischemic stroke model experiments. Similarly, PDGF-AB/BB may 
be administered intravenously rodents at the convalescent stage after transient MCAO, to see 





ischemic events. If therapeutic effects of these molecules could be ascertained in animal models, 
it would be of interest to conduct clinical trials to see whether the results can be translated from 
bench to bedside. Certainly, one factor of crucial importance for these studies is the timing of the 







The present thesis has demonstrated that some of the traditional prognostic markers such as CRP 
and sICAM-1 did not predict outcome in a cohort of non-disabled stroke patients at the 
convalescent stage. On the other hand, several novel markers have been found to predict outcome, 
such as sVCAM-1, a higher level of which was associated with a higher risk of death and 
recurrent vascular events, PDGF-AB/BB, a higher level of which was associated with a lower risk 
of recurrent vascular events, as well as VEGF, a higher level of which was associated with a 
lower risk of significant cognitive decline. Accordingly, sVCAM-1, PDGF-AB/BB and VEGF 
may serve as prognostic markers and potential therapeutic targets for ischemic stroke. 
Additionally, sVCAM-1, MIG, and IL-16 levels were found to correlate with baseline MMSE 
score, which suggests that interpretation these markers may be of use for evaluating post-stroke 
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